

# Relationship Between Glycated Hemoglobin and Stroke Risk: A Systematic Review and Meta-Analysis

John Peter Mitsios, B-BMED, MD; Elif Ilhan Ekinici, MBBS, FRACP, PhD; Gregory Peter Mitsios; Leonid Churilov, BSc(Hons), PhD; Vincent Thijs, MD, PhD

**Background**—Diabetes mellitus is a major risk factor for ischemic stroke. Rising hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>) levels are associated with microvascular diabetes mellitus complication development; however, this relationship has not been established for stroke risk, a macrovascular complication.

**Methods and Results**—We conducted a systematic review and meta-analysis of observational cohort and nested case-control cohort studies assessing the association between rising HbA<sub>1c</sub> levels and stroke risk in adults (≥18 years old) with and without type 1 or type 2 diabetes mellitus. Random-effects model meta-analyses were used to calculate pooled adjusted hazard ratios (HRs) and their precision. The systematic review yielded 36 articles, of which 29 articles (comprising n=532 779 participants) were included in our meta-analysis. Compared to non-diabetes mellitus range HbA<sub>1c</sub> (<5.7%), diabetes mellitus range HbA<sub>1c</sub> (≥6.5%) was associated with an increased risk of first-ever stroke with average HR (95% confidence interval) of 2.15 (1.76, 2.63), whereas pre-diabetes mellitus range HbA<sub>1c</sub> (5.7–6.5%) was not (average HR [95% confidence interval], 1.19 [0.87, 1.62]). For every 1% HbA<sub>1c</sub> increment (or equivalent), the average HR (95% confidence interval) for first-ever stroke was 1.12 (0.91, 1.39) in non-diabetes mellitus cohorts and 1.17 (1.09, 1.25) in diabetes mellitus cohorts. For every 1% HbA<sub>1c</sub> increment, both non-diabetes mellitus and diabetes mellitus cohorts had a higher associated risk of first-ever ischemic stroke with average HR (95% confidence interval) of 1.49 (1.32, 1.69) and 1.24 (1.11, 1.39), respectively.

**Conclusions**—A rising HbA<sub>1c</sub> level is associated with increased first-ever stroke risk in cohorts with a diabetes mellitus diagnosis and increased risk of first-ever ischemic stroke in non-diabetes mellitus cohorts. These findings suggest that more intensive HbA<sub>1c</sub> glycemic control targets may be required for optimal ischemic stroke prevention. (*J Am Heart Assoc.* 2018;7:e007858. DOI: 10.1161/JAHA.117.007858.)

**Key Words:** cerebrovascular disease/stroke • diabetes mellitus • hemoglobin A<sub>1c</sub> • meta-analysis • risk

Strokes represent a heterogeneous group of vascular pathologies that collectively act as a major global burden of mortality and lifelong morbidity. Diabetes mellitus is a major risk factor for the development of stroke, particularly ischemic stroke, with type 2 diabetes mellitus alone known to increase stroke risk 1.5 to 4 fold.<sup>1</sup> Macrovascular complications of diabetes mellitus (ischemic heart disease (IHD), stroke, and peripheral vascular disease) represent a major cause of diabetes mellitus related mortality and health-related expenditure.<sup>2,3</sup>

Glycated hemoglobin (HbA<sub>1c</sub>) is a validated marker of 2 to 3 month glycemic control used within routine diabetes mellitus care. Current American Diabetes Association (ADA) diabetes mellitus management guidelines recommend a base target of HbA<sub>1c</sub> <7.0% within routine diabetes mellitus care of non-pregnant adults.<sup>4</sup> This target is most validated for microvascular complication risk reduction and has unclear implications for optimal macrovascular risk reductions. Long-term follow-up studies of 2 randomized controlled trials (RCTs) have

From the University of Melbourne, Parkville, Melbourne, Victoria, Australia (J.P.M., E.I.E., G.P.M., L.C., V.T.); Austin Health, Heidelberg, Melbourne, Victoria, Australia (J.P.M.); The Florey Institute of Neuroscience & Mental Health, Melbourne, Victoria, Australia (J.P.M., L.C.); Departments of Endocrinology (E.I.E.) and Neurology (V.T.), Austin Health, Heidelberg, Melbourne, Victoria, Australia; Stroke Division, The Florey Institute of Neuroscience & Mental Health, University of Melbourne, Heidelberg, Melbourne, Victoria, Australia (V.T.).

Accompanying Datas S1 through S4, Tables S1 through S6, and Figures S1 through S23 are available at <http://jaha.ahajournals.org/content/7/11/e007858/DC1/embed/inline-supplementary-material-1.pdf>

The abstract of this work was presented as an oral presentation at the Stroke Society of Australasia Conference, August 23 to 25, 2017, in Queenstown, New Zealand, and as a poster presentation at the Australian Diabetes Society Conference, August 30 to September 1, 2017, in Perth, Australia.

**Correspondence to:** John Peter Mitsios, B-BMED, MD, P.O. Box 281, Abbotsford, Victoria, Australia 3067. E-mail: mitsios.jp@gmail.com

Received October 14, 2017; accepted March 2, 2018.

© 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

## Clinical Perspective

### What Is New?

- Using a meta-analytical approach, we found that higher glycated hemoglobin levels were associated with an increased risk of first-ever ischemic stroke in both non-diabetes mellitus and diabetes mellitus cohorts.
- In people with established diabetes mellitus, higher glycated hemoglobin levels were associated with an increased risk of first-ever stroke.

### What Are the Clinical Implications?

- Further interventional studies are needed to examine the effectiveness of more intensive glycemic control targets as part of primary and secondary stroke prevention, in pre-diabetes mellitus and diabetes mellitus cohorts.

demonstrated beneficial effects on long-term macrovascular outcomes with more intensive glycemic control, thereby suggesting a metabolic memory effect for hyperglycemia.<sup>5,6</sup>

Up to one half of all patients presenting with acute stroke have previously unknown abnormalities of glucose tolerance, with 20% to 40% of patients presenting with hyperglycemia at hospital admission.<sup>7</sup> Chronic hyperglycemia has been linked with several stroke risk factors including accelerated atherosclerosis, increased carotid intima media thickness (CIMT), cardiomyocyte dysfunction, atrial fibrillation (AF), and ischemic heart disease.<sup>8–11</sup> In non-diabetes mellitus patients with insulin resistance and recent ischemic stroke or transient ischemic attack, long-term treatment with pioglitazone reduced the risk of adverse cardiovascular outcomes.<sup>12</sup> The outcomes of this trial suggested that in the ischemic stroke subgroup, anti-hyperglycemic medication may need to start at lower HbA<sub>1c</sub> thresholds than currently accepted levels.<sup>12</sup>

No systematic review and meta-analysis has generated consensus regarding the specific relationship between rising HbA<sub>1c</sub> level and stroke risk.<sup>13,14</sup> We therefore aimed to fill this knowledge gap by conducting a systematic review and meta-analysis of observational studies to examine and determine a quantifiable risk relationship for the association between rising HbA<sub>1c</sub> level and stroke risk, stratified by diabetes mellitus status, stroke temporality, and stroke subtype.

## Methods

### Study Design and Registration

We systematically reviewed cohort and nested case-control cohort studies that assessed the association between varying HbA<sub>1c</sub> level and stroke risk. The protocol implemented as part of this systematic review and meta-analysis was constructed

using the combined recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA),<sup>15</sup> Meta-analysis of Observational Studies in Epidemiology (MOOSE) group,<sup>16</sup> and the Cochrane Handbook for Systematic Reviews.<sup>17</sup> This study is registered with PROSPERO (CRD42017056706). The data, analytic methods, and study materials will be/have been made available to other researchers for purposes of reproducing the results or replicating the procedure. These are available within this manuscript and the associated online data supplement.

### Literature Search Strategy

A systematic search of 5 literary databases (MEDLINE, Embase, PubMed, Web of Science, and the Cochrane Library) was performed between February 7, 2017, and March 5, 2017. Medical Subject Headings (MeSH) terms selected were synonymous with the following text words used: *glycosylated h(a)emoglobin, HbA<sub>1c</sub>, glycated h(a)emoglobin, stroke, cerebral infarction, cerebral h(a)emorrhage, and transient isch(a)emic attack.* MeSH terms were “exploded” to maximise coverage.

Search results were restricted to human ( $\geq 18$  years old) and English only articles. No publication filters were applied within any database. Search results were managed and duplicate entries removed using EndNote X7.7.1. A manual search of study references was performed for completeness. A complete list of MeSH and text words with Boolean operators applied within MEDLINE are provided in Figure S1.

### Inclusion and Exclusion Criteria

Studies were considered for inclusion within meta-analyses and sensitivity analyses performed if they met the following criteria: (1) presented adjusted hazard ratios (HRs) or risk ratios (RRs, relative risk) for the association between varying HbA<sub>1c</sub> level and stroke risk, defined by temporality (first-ever or recurrent) and subtype of event (ischemic, hemorrhagic, other); and (2) involved a minimum follow-up period of  $\geq 12$  months.

We excluded studies that met any of the following criteria: (1) failed the automatic exclusion criteria within the Scottish Intercollegiate Guidelines Network (SIGN)<sup>18</sup> quality tool (Data S1); (2) focused on specific subpopulations (including end-stage kidney disease (ESKD), dialysis, post-thrombolysis (tPA), post-myocardial infarction (AMI), and post-operative cohorts); (3) had insufficient or missing data for extrapolation and quality assessment; and (4) compared diabetes mellitus to non-diabetes mellitus cohorts.

In the source literature, effect sizes (HR or RR) were variably adjusted for covariates, with multiple effect sizes often reported. Consequently, we extracted the most extensively covariate-adjusted HR or RR data for use in the meta-analysis. However, if in the original source article adjustment

was performed for hypoglycemic medication use, we only included data that were not adjusted for hypoglycemic medication use, as the medication may have biased the association between the exposure and outcome. Data S2 provides a full description of inclusion and exclusion criteria applied during each phase of the search strategy.

## Search Protocol Implementation and Data Extraction

Two reviewers (J.P.M., G.P.M.) independently screened all available articles by title and abstract using predefined inclusion and exclusion criteria. Following this, 2 reviewers (J.P.M., V.T.) performed a full-text review of articles identified through screening using predefined inclusion and exclusion criteria. Objective methodological study quality assessment was performed during full-text review using 2 critical appraisal checklists for cohort studies.<sup>18,19</sup> Any disagreements were resolved through discussion between reviewers. Narrative synthesis was performed for all studies deemed suitable for inclusion in the meta-analysis (n=36 studies). Data on key study parameters, including; author(s), year of publication, study location, sample size, participant demography, stroke outcome type, effect size data, and covariate adjustment performed, were extracted in duplicate and are detailed in Tables S1 through S6. Any discrepancies in data extracted were resolved through consultation between authors.

## Statistical Analyses and Bias Assessment

The primary outcome measure of interest was the association between rising categorical or 1% increment (or equivalent) HbA<sub>1c</sub> levels and stroke risk, stratified by diabetes mellitus status, stroke temporality, and stroke subtype. A random-effects model was used for all meta-analyses and sensitivity analyses. Meta-analyses were only performed on strata that contained a minimum of 3 studies (n≥3) to ensure adequate analytical power. RR data were treated as equivalent to HR data in all analyses.

The association between rising categorical HbA<sub>1c</sub> levels and first-ever stroke risk was assessed through comparison of stroke risk between American Diabetes Association–defined non–diabetes mellitus range HbA<sub>1c</sub> (<5.7%) (reference category) to pre–diabetes mellitus range HbA<sub>1c</sub> (5.7%–6.5%) and diabetes mellitus range HbA<sub>1c</sub> (≥6.5%) categories. Only studies that used a reference category within non–diabetes mellitus range HbA<sub>1c</sub> and at least 1 comparator category within pre–diabetes mellitus range or diabetes mellitus range HbA<sub>1c</sub> were included (Data S3, Figures S2 and S3).

The association between 1% increments (or equivalent) of HbA<sub>1c</sub> and first-ever stroke risk was examined. Studies

reporting 1 standard deviation (1sd) increment effect sizes were treated as equivalent to 1% HbA<sub>1c</sub>, as the magnitude of these 1 standard deviation increments ≈ 1% increments (1±0.4%) and the effect sizes quoted approximated the estimated 1% increment equivalents (Tables S1– S6).

Many studies only reported categorical data. A linear regression model was used to estimate natural log-transformed 1% increment effect sizes and 95% confidence interval (CI) from this pool of categorical data using a method described by Greenland,<sup>20</sup> with statistical significance set at P<0.05. This estimated 1% data were then used within separate random-effects model meta-analyses performed. A detailed description of this method is provided in Data S4, Figures S4 and S5.

To avoid duplicate data use, whenever 2 studies reported on the same study population, we used the most recent study for the subgroup meta-analysis performed. Baseline and time-update mean values of HbA<sub>1c</sub> were treated as equivalents. Time-updated HbA<sub>1c</sub> values were selected in preference to single baseline values in studies that presented both. A random-effects model was used to generate overall effect sizes from effect size data that had been stratified by variables like sex or ethnicity.

Definitions used to classify stroke and diabetes mellitus status varied greatly within the source literature. Diabetes mellitus status was defined using reported diabetes mellitus status (medical history, clinician or patient reported) and/or glucose or HbA<sub>1c</sub> measurement at study inclusion. Strokes were classified using *International Classification of Diseases, Ninth/Tenth Revision (ICD-9/10)* codes, World Health Organization criteria and/or study-defined stroke criteria. Stroke event occurrence was identified using hospital admission diagnosis, death certificate details, medical history details, clinician reports, and/or patient-reported status.

Given the heterogeneity in diabetes mellitus and stroke outcome classification and reporting, the decision was made to assign both diabetes mellitus and stroke outcome status based on each study's reported outcome status. Effect sizes adjusted for diabetes mellitus status were treated as representing non–diabetes mellitus data. Effect sizes adjusted for past stroke history were treated as representing first-ever stroke data.

Several sensitivity analyses were performed within this study, examining the; (1) effect of combining type 1 and type 2 diabetes mellitus cohorts, (2) importance of ischemic subtype stratification, (3) difference between estimated and quoted 1% HbA<sub>1c</sub> increment data, and (4) effect of varying levels of covariate adjustment on results obtained. These sensitivity analyses are presented in Figures S6 through S10. The linear-regression estimated 1% HbA<sub>1c</sub> meta-analyses are presented in Figure S11.

Based on the recommendations of the Cochrane Handbook,<sup>17</sup> we did not perform formal meta-regression because of insufficient study number ( $n < 10$  studies per subgroup). We assessed for statistical heterogeneity using the  $I^2$  statistic. As per Higgins et al,<sup>21</sup> we assigned adjectives of “low,” “moderate,” and “high” for  $I^2$  statistic values of 25%, 50% and 75%, respectively.  $I^2$  statistic values below 25% were assigned the adjective of “low.” The  $I^2$  statistic describes the percentage of variation across studies that is attributable to heterogeneity rather than chance.<sup>21</sup> Consequently, the categories of  $I^2$  statistic magnitude outlined do not refer to the absolute amount of observed heterogeneity.

Publication bias was assessed through construction of funnel plots and performing Egger’s test for funnel plot asymmetry for each meta-analysis performed (Figures S12–S16). Statistical significance for publication bias assessment using Egger’s test was set at  $P < 0.05$ . Stata/IC 14.2 was used for all statistical analyses. Additional sensitivity analyses are presented in Figures S17 through S23.

## Results

A total of 5831 articles were identified through the search strategy. Following duplicate removal ( $n = 2279$ ), a total of 3552 articles were screened by title and abstract. Of these, 310 articles were assessed by full-text review. A total of 56 studies were assessed for inclusion in meta-analyses performed, of which 20 were excluded for the following reasons: 7 studies did not provide HR or RR data; 3 studies provided only effect sizes adjusted for hypoglycemic medication use; 5 studies provided effect sizes which compared diabetes mellitus to non-diabetes mellitus participants; 1 study provided HR which compared intensively treated to non-intensively treated cohorts; 1 study had effect size covariate adjustment and stratification limitations; 1 study used a duplicate study population with incomplete HbA<sub>1c</sub> strata use in effect size calculation; 1 study used a conditional HR that compared stroke and non-stroke patient cohorts; and 1 study used a pooled cardiovascular disease outcome without stratifying for a stroke outcome. A detailed overview of the study review process is presented in Figure 1.<sup>22–41</sup>

Of the 36 studies deemed suitable for meta-analysis, 7 reported recurrent stroke outcome data and were included only in narrative synthesis because of concerns regarding underpowering of meta-analyses following outcome stratification (Tables S1–S6). A total of 29 studies comprising 532 779 participants were used in meta-analyses and sensitivity analyses (Figure 1<sup>22–41</sup>). A narrative summary of baseline participant characteristics within all 36 articles identified for potential inclusion is provided in Tables S1 through S6.

## First-Ever Stroke Risk in American Diabetes Association–Defined HbA<sub>1c</sub> Ranges

Compared to non-diabetes mellitus range HbA<sub>1c</sub> ( $< 5.7\%$ ), pre-diabetes mellitus range HbA<sub>1c</sub> ( $5.7\%–6.5\%$ ) was not associated with a significant increased risk of first-ever stroke (average HR [95% CI], 1.19 [0.87, 1.62]). In contrast, diabetes mellitus range HbA<sub>1c</sub> ( $\geq 6.5\%$ ) was associated with a significant increased risk of first-ever stroke when compared to non-diabetes mellitus range HbA<sub>1c</sub> (average HR [95% CI], 2.15 [1.76, 2.63]).

We identified moderate and low  $I^2$  statistic values ( $I^2 = 61.3\%$  [ $P = 0.051$ ] and  $I^2 = 0\%$  [ $P = 0.460$ ]) for the pre-diabetes mellitus and diabetes mellitus analyses, respectively. We did not find evidence of significant publication bias for either analysis (Figure S12).


## Association Between Study-Quoted 1% HbA<sub>1c</sub> Increments and First-Ever Stroke Risk

Figure 2<sup>42–53</sup> summarizes the meta-analyses assessing the association between study-quoted rising 1% HbA<sub>1c</sub> increments and first-ever stroke risk, stratified by diabetes mellitus status and ischemic stroke subtype. For every 1% HbA<sub>1c</sub> increment (or equivalent), the average HR (95% CI) for first-ever stroke risk was 1.12 (0.91, 1.39) in non-diabetes mellitus cohorts and 1.17 (1.09, 1.25) in diabetes mellitus cohorts. When restricted to studies only examining first-ever ischemic stroke, average HRs (95% CI) were 1.49 (1.32, 1.69) and 1.24 (1.11, 1.39) for non-diabetes mellitus and diabetes mellitus cohorts, respectively.

The  $I^2$  statistic value was moderate for the analysis assessing first-ever stroke risk in patients with diabetes mellitus ( $I^2 = 59.0\%$ ,  $P = 0.012$ ). Sensitivity analysis identified studies with limited covariate adjustment as the likely source of this moderate  $I^2$  statistic value (Figure S6). Exclusion of these studies reduced the  $I^2$  statistic value from moderate to low (reduction from  $I^2 = 59.0\%$  [ $P = 0.012$ ] to  $I^2 = 41.9\%$  [ $P = 0.111$ ]) without inducing significant publication bias or altered pooled effect size significance (average HR [95% CI], 1.14 [1.07, 1.20] prior to exclusion and 1.17 [1.09, 1.25] following exclusion). We did not find evidence of significant publication bias in any subgroup analysis (Figures S13 and S14).

## Association Between Linear Regression Estimated 1% HbA<sub>1c</sub> Increments and First-Ever Stroke Risk


For every estimated 1% HbA<sub>1c</sub> increment (or equivalent), the average HR (95% CI) for first-ever stroke was 1.17 (1.02, 1.34) and 1.17 (1.01, 1.36) for non-diabetes mellitus



**Figure 1.** PRISMA flowchart outlining search strategy implementation and results at each stage. Results presented outline the number of articles identified during each stage of the search strategy. Duplicate removal was performed using the default duplicate removal function within EndNote X7.7.1. Screening by title and abstract was performed independently by 2 researchers using a defined set of inclusion criteria. Full-text review, including methodological quality assessment, was subsequently performed using defined inclusion criteria. Following this, articles were assessed for meta-analytical inclusion through consultation between 2 authors using a separate set of inclusion criteria. Articles deemed suitable for meta-analyses and sensitivity analyses were stratified based on cohort diabetes mellitus status and stroke outcome. Strata that lacked sufficient article number ( $n < 3$  articles) were presented within narrative synthesis only. A total of 29 articles were used in meta-analyses and sensitivity analyses conducted. The number of studies at each stage ( $n$ ) is reflected in brackets. AMI indicates acute myocardial infarction; CADASIL, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL); CVD, cardiovascular disease; ESKD, end-stage kidney disease; HR, hazard ratio; RR, risk ratio (relative risk); tPA, tissue plasminogen activator.

and diabetes mellitus cohorts, respectively. When restricted to first-ever ischemic stroke, average HRs (95% CI) were 1.35 (0.91, 2.02) and 1.32 (1.23, 1.42) for non-diabetes mellitus and diabetes mellitus cohorts, respectively (Figure S11). Inclusion of studies with limited covariate

adjustment resulted in a high  $I^2$  statistic value, as shown in Figure S7. Exclusion of these studies resulted in a reduction of the  $I^2$  statistic value from high to moderate (reduction from  $I^2=89.9\%$  [ $P < 0.001$ ] to  $I^2=57.7\%$  [ $P=0.051$ ]) without inducing statistically significant publication bias



**Figure 2.** Association between study-quoted rising 1% HbA<sub>1c</sub> increments and stratified first-ever stroke risk. Studies presenting hazard ratio (HR) or risk ratio (RR, relative risk) data assessing the association between rising 1% HbA<sub>1c</sub> increments and first-ever stroke risk were identified and used to calculate meta-analytical effect sizes (ES) (95% CI). RR data were treated as equivalent to HR data. Studies using 1 standard deviation (1 SD) HbA<sub>1c</sub> increments for effect sizes quoted were treated as equivalent to 1% HbA<sub>1c</sub> increment data. The corresponding HbA<sub>1c</sub> increments for each standard deviation are as shown in brackets. Studies were stratified based on the diabetes mellitus status of their cohorts and their restriction of first-ever stroke to an ischemic stroke subtype. The outcome “first-ever stroke” reflects any stroke subtype. The outcome “first-ever ischemic stroke” included only studies that specifically restricted their stroke outcome to first-ever stroke of ischemic subtype. Diabetes cohorts included studies that measured type 1 diabetes mellitus (T1DM), type 2 diabetes (T2DM) or a combination of both (mixed diabetes mellitus cohort). Non-diabetes mellitus cohorts represented studies that used participants with no diabetes mellitus or whose effect size(s) were adjusted for diabetes mellitus. The I<sup>2</sup> statistic values for each subgroup analysis assessing the percentage of variation across studies that is due to heterogeneity, rather than chance, are presented below each subgroup analysis. A random-effects model using the inverse-variance method for weighting was used to generate pooled effect sizes for each subgroup. ES=1.0 indicates no statistically significant association.

(Figures S15 and S16) or altering the significance of the pooled effect sizes (average HR [95% CI], 1.21 [1.05, 1.40] prior to exclusion and 1.17 [1.01, 1.36] following exclusion).

## Discussion

We demonstrated a significant association between rising 1% HbA<sub>1c</sub> increments and first-ever stroke risk in cohorts with

diabetes mellitus. In non-diabetes mellitus cohorts, analysis of estimated 1% HbA<sub>1c</sub> data revealed a significant relationship with first-ever stroke, while study-quoted 1% HbA<sub>1c</sub> data analyses were significant only for an association with first-ever ischemic stroke. Analysis of American Diabetes Association diabetes mellitus range HbA<sub>1c</sub> (≥6.5%) revealed a significant 2.15-fold increased risk of first-ever stroke in diabetes mellitus range HbA<sub>1c</sub> compared to non-diabetes mellitus range HbA<sub>1c</sub> (<5.7%).

The absence of a clear association between pre-diabetes mellitus range HbA<sub>1c</sub> and first-ever stroke identified is in keeping with the results of a previous meta-analysis by Huang et al.<sup>54</sup> This study identified a nonsignificant 5% increased risk of stroke associated with pre-diabetes mellitus range HbA<sub>1c</sub> following meta-analysis of only 2 studies.<sup>54</sup>

Our study expands upon previous meta-analyses.<sup>13,14</sup> These studies demonstrated a significant association between rising 1% HbA<sub>1c</sub> increments and stroke risk in patients with type 2 diabetes mellitus (where stroke represented any fatal or nonfatal stroke event) after combining study-quoted and estimated 1% HbA<sub>1c</sub> data from a small number of included studies.

Our study addressed these limitations. Our study included 29 studies and studied ischemic stroke specifically. The use of separate meta-analyses for study-quoted and linear regression estimated 1% HbA<sub>1c</sub> data within our meta-analysis avoids the inherent imputation bias associated with conversion of categorical data into a continuous data set.

Our study suggests the presence of an independent association between chronic hyperglycemia, even in the pre-diabetes mellitus range, and first-ever stroke risk. The strength of this association was enhanced when restricting stroke outcomes to first-ever ischemic stroke. This suggests that the inclusion of hemorrhagic and undefined stroke subtypes within the stroke outcome assessed may have blunted the statistical significance of the underlying relationship between hyperglycemia and ischemic stroke. This finding is in keeping with previous research that has suggested that diabetes mellitus is primarily a risk factor for ischemic stroke rather than hemorrhagic stroke,<sup>7</sup> and is supported by pathogenic data that links chronic hyperglycemia and ischemic stroke risk factors.<sup>8-11</sup>

The DCCT/EDIC (Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study) demonstrated a statistically significant risk reduction in macrovascular complication risk in participants managed initially with intensive glycemic control measures following 17 years of follow-up of a type 1 diabetes mellitus population.<sup>5,55</sup> Similarly, the UKPDS (United Kingdom Prospective Diabetes Study) follow-up study<sup>6</sup> demonstrated that intensive glycemic control in patients with type 2 diabetes mellitus led to fewer macrovascular complications after prolonged follow-up, suggesting a metabolic memory effect for earlier intensive control.

Despite this, several randomized controlled trials including VADT (Veterans Affairs Diabetes Trial),<sup>56</sup> ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicon Modified Release Controlled Evaluation)<sup>57</sup> and ACCORD (Action to Control Cardiovascular Risk in Diabetes)<sup>58</sup> have refuted the presence of a statistically significant macrovascular complication risk reduction offered by intensified glycemic control, in the

context of type 2 diabetes mellitus management. Common limitations within these randomized controlled trials that may explain the incongruence of their results with DCCT/EDIC and UKPDS include; the comparatively short follow-up intervals used, competing risk confounding associated with the older age of participants used, the inclusion of participants with poorly controlled diabetes mellitus, and, importantly, the inclusion of participants with preexisting cardiovascular disease (may be at heightened risk of hypoglycemia with insulin and sulfonylurea therapy). Newer agents reduce cardiovascular outcomes without major changes in HbA<sub>1c</sub> or improved glycemic control, but these may act through other pathways and do not deter from the finding that pre-diabetes mellitus, as determined by HbA<sub>1c</sub> level, appears associated with incident ischemic stroke.<sup>59</sup> This is evident within 2 recent glucagon-like peptide-1 trials that demonstrated significant reductions in a combined cardiovascular outcome of cardiovascular death, nonfatal acute myocardial infarction, or nonfatal stroke through their use in type 2 diabetes mellitus populations with high cardiovascular disease risk.<sup>60,61</sup>

Several measures were implemented within our study with the intention of reducing the magnitude of interstudy heterogeneity. We attempted to reduce heterogeneity by implementing an extensive set of inclusion and exclusion criteria that were designed to reduce common sources of heterogeneity and bias, including but not limited to; variability in study design, variability in effect measures used, insufficient follow-up time, and insufficient covariate adjustment. Given the implicit heterogeneity of observational study designs, a random-effects model was used in all analyses performed. The use of subgroup meta-analyses, stratified for key outcome parameters including stroke subtype (first-ever ischemic stroke versus first-ever stroke) and cohort diabetes mellitus status (diabetes mellitus versus non-diabetes mellitus cohorts), further aimed to reduce outcome measure related heterogeneity.

Of the subgroup meta-analyses focusing on the association between rising 1% HbA<sub>1c</sub> increments and first-ever stroke risk, only 2 demonstrated I<sup>2</sup> values exceeding 25%, thereby indicating a very good level of heterogeneity control through our study design. Sensitivity analyses performed in Figures S6 and S7 demonstrated reductions in the magnitude of heterogeneity detected from moderate to low and high to moderate, respectively, following exclusion of studies with limited covariate adjustment. Given this result, it is a reasonable assertion that differences in the types and number of covariates adjusted for within individual studies is a likely major contributor to the statistical heterogeneity measured. This is not surprising when considering that many of these variables, including; age, sex, hypertension, smoking status, cholesterol level, and history of cardiovascular disease, are independent risk factors for the development of vascular disease including stroke.

A further potential reason for the statistical heterogeneity measured relates to the unavoidable differences in study definitions for key parameters of diabetes mellitus status and stroke. Decisions made relating to the treatment of studies whose results were statistically adjusted for past history of diabetes mellitus and stroke, and the acceptance of study-quoted diabetes mellitus and stroke outcome descriptors may also have contributed to the level of statistical heterogeneity detected but were unavoidable given the inherent variability in outcome definitions present within observational study designs.

Our study has limitations. We restricted our studies to those reporting only RR and HR data. The lack of a common, standardized definition for diabetes mellitus across all the studies could result in assessment bias. Likewise, the inclusion of studies with different stroke outcome classification systems is suboptimal given the inherent differences within the classification systems used. The use of a linear regression model to  $\approx 1\%$  HbA<sub>1c</sub> effect size data from categorical HbA<sub>1c</sub> data can provide only an approximation of this relationship and could not be combined with quoted data. The variability in covariate adjustment performed (types and number of covariates adjusted for) within the source studies included in our analyses imposed limitations on our ability to examine the independent effects of individual covariate adjustment on the statistical heterogeneity calculated using the  $I^2$  statistic. Likewise, the limited number of studies ( $n < 10$ ) within each subgroup meta-analysis performed precluded the implementation of meta-regression techniques.

Although a comprehensive search strategy assessing multiple literary databases was performed, we may not have identified all relevant literature on this topic. We also did not include studies addressing this topic in languages other than English. We did not have access to individual patient data that would have permitted more detailed analyses. Our data are, however, in line with an individual patient data meta-analysis that assessed the risk of a composite outcome of stroke and myocardial infarction with varying levels of HbA<sub>1c</sub>.<sup>62</sup> That study did not report on stroke outcomes separately but was able to identify an increased risk of acute myocardial infarction/stroke in patients with low levels of HbA<sub>1c</sub>.<sup>62</sup> Our methodology was not able to identify such a J-shaped relationship. The limited number of articles within each subgroup analysis prevented use of formal meta-regression and analysis of HbA<sub>1c</sub> as a risk factor for recurrent stroke.

## Conclusions

In summary, our study suggests that both continuous and categorical elevations in HbA<sub>1c</sub> are associated with increased first-ever ischemic stroke risk, irrespective of diabetes mellitus status. Prevention of macrovascular complications

like stroke may need to start at lower HbA<sub>1c</sub> thresholds. Further interventional studies are needed to explore the effectiveness of more intensive glycemic management within primary and secondary stroke prevention, in pre-diabetes mellitus and diabetes mellitus cohorts.

## Acknowledgments

Special thanks to Ms Helen Baxter (Clinical Librarian, Austin Health Services Library, Austin Health) for her advice regarding selection of search terms, literature databases and Boolean operators during search strategy development. The Florey Institute of Neuroscience and Mental Health acknowledges the strong support from the Victorian Government and in particular the funding from the Operational Infrastructure Support Grant.

## Sources of Funding

E.I.E. was supported by a Viertel Clinical Investigatorship, RACP Fellowship, and Sir Edward Weary Dunlop Medical Research Foundation research grant and a Stroke Foundation grant.

## Disclosures

V.T. reports receiving consulting fees from Medtronic. V.T. is on the steering committee of the DIAGNOSE AF and REACT AF clinical trials sponsored by Medtronic. V.T. reports speaker and consulting fees and travel support by Boehringer Ingelheim, Pfizer/BMS, Daichi-Sankyo, and Bayer. The remaining authors have no disclosures to report.

## References

1. Fowler MJ. Microvascular and macrovascular complications of diabetes. *Clin Diabetes*. 2008;26:77–82.
2. Wild SH, Dunn CJ, McKeigue PM, Comte S. Glycemic control and cardiovascular disease in type 2 diabetes: a review. *Diabetes Metab Res Rev*. 1999;15:197–204.
3. Hogan P, Dall T, Nikolov P; American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. *Diabetes Care*. 2003;26:917–932.
4. American Diabetes Association. 5. Glycemic targets. *Diabetes Care*. 2016;39 (suppl 1):S39–S46.
5. Nathan DM, Cleary PA, Backlund JYC, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; DCCT/EDIC Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med*. 2005;353:2643–2653.
6. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med*. 2008;359:1577–1589.
7. Baird TA, Parsons MW, Barber PA, Butcher KS, Desmond PM, Tress BM, Colman PG, Jerums G, Chambers BR, Davis SM. The influence of diabetes mellitus and hyperglycaemia on stroke incidence and outcome. *J Clin Neurosci*. 2002;9:618–626.
8. Pai JK, Cahill LE, Hu FB, Rexrode KM, Manson JE, Rimm EB. Hemoglobin A1c is associated with increased risk of incident coronary heart disease among apparently healthy, nondiabetic men and women. *J Am Heart Assoc*. 2013;2:e000077. doi: 10.1161/JAHA.112.000077.
9. Kobayashi S, Xu X, Chen K, Liang Q. Suppression of autophagy is protective in high glucose-induced cardiomyocyte injury. *Autophagy*. 2012;8:577–592.



10. Qi W, Zhang N, Korantzopoulos P, Letsas KP, Cheng M, Di F, Tse G, Liu T, Li G. Serum glycosylated hemoglobin level as a predictor of atrial fibrillation: a systematic review with meta-analysis and meta-regression. *PLoS One*. 2017;12:e0170955.
11. Vitelli LL, Shahar E, Heiss G, McGovern PG, Brancati FL, Eckfeldt JH, Folsom AR; Atherosclerosis Risk in Communities (ARIC) Study Investigators. Glycosylated hemoglobin level and carotid intimal-medial thickening in nondiabetic individuals. The Atherosclerosis Risk in Communities Study. *Diabetes Care*. 1997;20:1454–1458.
12. Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams HP, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O'Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR; for the IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. *N Engl J Med*. 2016;374:1321–1331.
13. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. *Ann Intern Med*. 2004;141:421–431.
14. Zhang Y, Hu G, Yuan Z, Chen L. Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis. *PLoS One*. 2012;7:e42551.
15. Moher D, Liberati A, Tetzlaff J, Altman DG; The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*. 2009;6:e1000097.
16. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB; for the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) Group. Meta-analysis of observational studies in epidemiology: a proposal for reporting. *JAMA*. 2000;283:2008–2012.
17. Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Internet]*. Oxford, England: The Cochrane Collaboration; 2011. Available at: [www.handbook.cochrane.org](http://www.handbook.cochrane.org). Accessed March 21, 2017.
18. SIGN Methodology Checklist 3: cohort studies. Edinburgh, Scotland: Scottish Intercollegiate Guideline Network; 2012. Available at: [http://www.sign.ac.uk/assets/checklist\\_for\\_cohort\\_studies.rtf](http://www.sign.ac.uk/assets/checklist_for_cohort_studies.rtf). Accessed March 21, 2017.
19. JBI critical appraisal checklist for cohort studies. South Australia: The Joanna Briggs Institute; 2016. Available at: [http://joannabriggs.org/assets/docs/critical-appraisal-tools/JBI\\_Critical\\_Appraisal-Checklist\\_for\\_Cohort\\_Studies.pdf](http://joannabriggs.org/assets/docs/critical-appraisal-tools/JBI_Critical_Appraisal-Checklist_for_Cohort_Studies.pdf). Accessed March 21, 2017. Updated tool available from: [http://joannabriggs.org/assets/docs/critical-appraisal-tools/JBI\\_Critical\\_Appraisal-Checklist\\_for\\_Cohort\\_Studies2017.pdf](http://joannabriggs.org/assets/docs/critical-appraisal-tools/JBI_Critical_Appraisal-Checklist_for_Cohort_Studies2017.pdf).
20. Greenland S. Quantitative methods in the review of epidemiologic literature. *Epidemiol Rev*. 1987;9:1–30.
21. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327:557–560.
22. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ*. 2000;321:405–412.
23. Law ZK, Nafisah WN, Sahathevan R, Hing JY, Zakaria MF, Shuhari NMM, Ahmad NF, Ting TK, Tan HJ, Azmin S, Remli R, Nawi AM, Ibrahim NM. High prevalence of diabetes in stroke patients and its association with lacunar infarction. *Neuro Asia*. 2015;20:121–127.
24. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. *Stroke*. 1994;25:1157–1164.
25. Davis TME, Bruce DG, Davis WA. Predictors of first stroke in type 1 diabetes: the Fremantle Diabetes Study. *Diabet Med*. 2005;22:551–553.
26. Lehto S, Ronnema T, Pyorala K, Laakso M. Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. *Stroke*. 1996;27:63–68.
27. Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. *Diabetes Care*. 2004;27:201–207.
28. Kimura T, Kaneto H, Kanda-Kimura Y, Shimoda M, Kamei S, Anno T, Kawasaki F, Hashiramoto M, Matsuki M, Mune T, Kaku K. Seven-year observational study on the association between glycemic control and the new onset of macroangiopathy in Japanese subjects with type 2 diabetes. *Intern Med*. 2016;55:1419–1424.
29. Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Svensson AM, Gudbjornsdottir S, Eliasson B. New aspects of HbA<sub>1c</sub> as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). *J Intern Med*. 2010;268:471–482.
30. Gudbjornsdottir S, Eliasson B, Eeg-Olofsson K, Zethelius B, Cederholm J. Additive effects of glycaemia and dyslipidaemia on risk of cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register. *Diabetologia*. 2011;54:2544–2551.
31. Vazquez-Benitez G, Desai JR, Xu S, Goodrich GK, Schroeder EB, Nichols GA, Segal J, Butler MG, Karter AJ, Steiner JF, Newton KM, Morales LS, Pathak RD, Thomas A, Reynolds K, Kirchner HL, Waitzfelder B, Lafata JE, Adibhatla R, Xu Z, O'Connor PJ. Preventable major cardiovascular events associated with uncontrolled glucose, blood pressure, and lipids and active smoking in adults with diabetes with and without cardiovascular disease: a contemporary analysis. *Diabetes Care*. 2015;38:905–912.
32. Sunaga K, Miura K, Naruse Y, Sakurai M, Morikawa Y, Kurosawa Y, Nakagawa H. Glycated hemoglobin and risk of stroke, ischemic and hemorrhagic, in Japanese men and women. *Cerebrovasc Dis*. 2008;26:310–316.
33. Sakurai M, Saitoh S, Miura K, Nakagawa H, Ohnishi H, Akasaka H, Kadota A, Kita Y, Hayakawa T, Ohkubo T, Okayama A, Okamura T, Ueshima H; for the NIPPON DATA90 Research Group. HbA<sub>1c</sub> and the risks for all-cause and cardiovascular mortality in the general Japanese population. *Diabetes Care*. 2013;36:3759–3765.
34. Saliba W, Barnett-Griness O, Elias M, Rennert G. Glycated hemoglobin and risk of first episode stroke in diabetic patients with atrial fibrillation: a cohort study. *Heart Rhythm*. 2015;12:886–892.
35. Zhang Y, Galloway JM, Welty TK, Wiebers DO, Whisnant JP, Devereux RB, Kizer JR, Howard BV, Cowan LD, Yeh J, Howard WJ, Wang W, Best L, Lee ET. Incidence and risk factors for stroke in American Indians: the Strong Heart Study. *Circulation*. 2008;118:1577–1584.
36. Jing J, Pan Y, Zhao X, Zheng H, Jia Q, Li H, Guan L, Liu L, Wang C, Meng X, He Y, Wang Y, Wang Y. Prognosis of ischemic stroke with newly diagnosed diabetes mellitus according to hemoglobin A<sub>1c</sub> criteria in Chinese population. *Stroke*. 2016;47:2038–2044.
37. Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. *Cardiovasc Diabetol*. 2015;14:100.
38. Gosmanov AR, Lu JL, Sumida K, Potukuchi PK, Rhee CM, Kalantar-Zadeh K, Molnar MZ, Kovesdy CP. Synergistic association of combined glycemic and blood pressure level with risk of complications in US veterans with diabetes. *J Hypertens*. 2016;34:907–913.
39. Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HAW, Holman RR. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). *Diabetologia*. 2006;49:1761–1769.
40. Yang X, Kong APS, So WY, Ma RCW, Ho CS, Lam CWK, Chow CC, Cockram CS, Tong PCY, Chan JCN. Effects of chronic hyperglycaemia on incident stroke in Hong Kong Chinese patients with type 2 diabetes. *Diabetes Metab Res Rev*. 2007;23:220–226.
41. Yokoyama H, Matsushima M, Kawai K, Hirao K, Oishi M, Sugimoto H, Takeda H, Minami M, Kobayashi M, Sone H; on behalf of the Japan Diabetes Clinical Data Management Study Group. Low incidence of cardiovascular events in Japanese patients with type 2 diabetes in primary care settings: a prospective cohort study (JDDM 20). *Diabet Med*. 2011;28:1221–1228.
42. Birkenhager-Gillesse EG, den Elzen WPJ, Achterberg WP, Mooijaart SP, Gussieklo J, de Craen AJM. Association between glycosylated hemoglobin and cardiovascular events and mortality in older adults without diabetes mellitus in the general population: the Leiden 85-Plus Study. *J Am Geriatr Soc*. 2015;63:1059–1066.
43. Lawlor DA, Fraser A, Ebrahim S, Smith GD. Independent associations of fasting insulin, glucose and glycated haemoglobin with stroke and coronary heart disease in older women. *PLoS Med*. 2007;4:e263.
44. Chen YY, Lin YJ, Chong E, Chen PC, Chao TF, Chen SA, Chien KL. The impact of diabetes mellitus and corresponding HbA<sub>1c</sub> levels on the future risks of cardiovascular disease and mortality: a representative cohort study in Taiwan. *PLoS One*. 2015;10:e0123116.
45. Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Svensson AM, Gudbjornsdottir S, Eliasson B. Glycemic control and cardiovascular disease in 7,454 patients with type 1 diabetes: an observational study from the Swedish National Diabetes Register (NDR). *Diabetes Care*. 2010;33:1640–1646.
46. Freemantle N, Danchin N, Calvi-Gries F, Vincent M, Home PD. Relationship of glycaemic control and hypoglycaemic episodes to 4-year cardiovascular outcomes in people with type 2 diabetes starting insulin. *Diabetes Obes Metab*. 2016;18:152–158.
47. Elley CR, Kenealy T, Robinson E, Drury PL. Glycated haemoglobin and cardiovascular outcomes in people with type 2 diabetes: a large prospective cohort study. *Diabet Med*. 2008;25:1295–1301.
48. Moss SE, Klein R, Klein BEK, Meuer SM. The association of glycemia and cause-specific mortality in a diabetic population. *Arch Intern Med*. 1994;154:2473–2479.

49. Xu L, Chan WM, Hui YF, Lam TH. Association between HbA<sub>1c</sub> and cardiovascular disease mortality in older Hong Kong Chinese with diabetes. *Diabet Med*. 2012;29:393–398.
50. Hagg S, Thorn LM, Forsblom CM, Gordin D, Saraheimo M, Tolonen N, Waden J, Liebkind R, Putaala J, Tatlisumak T, Groop PH; on behalf of the FinnDiane Study Group. Different risk factor profiles for ischemic and hemorrhagic stroke in type 1 diabetes mellitus. *Stroke*. 2014;45:2558–2562.
51. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, Coresh J, Brancati FL. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. *N Engl J Med*. 2010;362:800–811.
52. Karas MG, Devereux RB, Wiebers DO, Whisnant JP, Best LG, Lee ET, Howard BV, Roman MJ, Umans JG, Kizer JR. Incremental value of biochemical and echocardiographic measures in prediction of ischemic stroke: the Strong Heart Study. *Stroke*. 2012;43:720–726.
53. Kranenburg G, van der Graaf Y, van der Leeuw J, Nathoe HMW, de Borst GJ, Kappelle LJ, Visseren FLJ, Westerink J; on behalf of the SMART Study Group. The relation between HbA<sub>1c</sub> and cardiovascular events in patients with type 2 diabetes with and without vascular disease. *Diabetes Care*. 2015;38:1930–1936.
54. Huang Y, Cai X, Mai W, Li M, Hu Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. *BMJ*. 2016;355:i5953.
55. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med*. 1993;329:977–986.
56. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; for the VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med*. 2009;360:129–139.
57. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2008;358:2560–2572.
58. Gerstein HC, Miller ME, Ismail-Beigi F, Largay J, McDonald C, Lochnan HA, Booth GL; for the ACCORD Study Group. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. *Lancet*. 2014;384:1936–1941.
59. Lipska KJ, Krumholz HM. Is hemoglobin A1c the right outcome for studies of diabetes? *JAMA*. 2017;317:1017–1018.
60. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsboll T; for the SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2016;375:1834–1844.
61. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; for the LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2016;375:311–322.
62. The Emerging Risk Factors Collaboration. Glycated hemoglobin measurement and prediction of cardiovascular disease. *JAMA*. 2014;311:1225–1233.

# **SUPPLEMENTAL MATERIAL**

## Data S1:

---

### Scottish Intercollegiate Guidelines Network (SIGN) methodological quality assessment tool [1] automatic exclusion criteria:

#### Criterion 1.7:

“The outcomes are clearly defined.”

#### Criterion 1.11:

“Evidence from other sources is used to demonstrate that the method of outcome assessment is valid and reliable.”

#### Criterion 1.13:

“The main potential confounders are identified and taken into account in the design and analysis.”

## Data S2:

---

### Inclusion and exclusion criteria for each phase of the search strategy:

#### Screening by title and abstract:

- Adults aged  $\geq 18$  yo
- Abstract available for assessment
- Human only studies
- Observational studies restricted to cohort and nested case-control cohort study designs
- Primary literature only (exclude reviews, systematic reviews and meta-analyses)
- Must include quantitative analysis of the association between HbA1c and one or more of the following:
  - o Stroke; defined by fatality of event (fatal/non-fatal), temporality of event (first-ever or recurrent) and/or subtype of stroke (ischaemic, haemorrhagic, other)
  - o Cardiovascular disease (CVD); only if there is inferred or explicit reference to quantitative analysis involving a stroke outcome within the study’s definition of CVD
  - o Post-acute stroke event mortality; only if there is inferred or explicit reference to recurrent stroke events being included as one of the potential causes of mortality measured by the study

### **Full-text review:**

- Adults aged  $\geq 18$  yo
- English full-text available for assessment
- Human only studies
- Observational studies restricted to cohort and nested case-control cohort study designs
- Minimum follow-up of  $\geq 12$  months
- Must include quantitative analysis of the association between HbA1c level and stroke risk using one of the following relative measures; odds ratio (OR), risk ratio (RR, relative risk) or hazard ratio (HR)
- **Exclude if:**
  - o Confounded by significant baseline morbidity (i.e. CADASIL patients, ESKD/dialysis patients and outcome measurement in post-operative patients (including post-AMI and post-tPA patients))- assessed on a case-by-case basis
  - o Do not meet the automatic exclusion criteria within the Scottish Intercollegiate Guidelines Network (SIGN)- criteria: 1.7, 1.11, 1.13.[1]
  - o Had insufficient data for methodological quality assessment and effect size extrapolation

### **Meta-analytical inclusion:**

Must present hazard ratio or risk ratio (relative risk) data which assessed the association between rising HbA1c level and stroke risk (first-ever or recurrent stroke), **and** have met the following criteria:

- Clearly defined diabetes status of the sample cohort used in HR or RR calculation, either non-diabetes or diabetes cohort (comparing non-diabetes to non-diabetes and diabetes to diabetes patients)- excluded studies with HR or RR data comparing diabetes to non-diabetes cohorts
- HR or RR data for the association between 1% HbA1c increments (or equivalent) **or** inter-categorical HbA1c elevations (with a defined reference category), and stroke risk.
- HR or RR data must **not** be adjusted for hypoglycaemic medication (diabetes medication) use

### Data S3:

---

#### Association between ADA defined pre-diabetes and diabetes range HbA1c and first-ever stroke risk

Studies presenting categorical HbA1c effect size data for a first-ever stroke outcome (not restricted to ischaemic stroke subtype) were considered for inclusion in the ADA HbA1c range inter-categorical meta-analyses performed if they met the following criteria:

- Reference category of HbA1c used was within the range of HbA1c included within the ADA-defined non-diabetes range HbA1c (<5.7%)
- At least one comparator category of HbA1c within the range of either a) ADA pre-diabetes range HbA1c (5.7%-6.5%) or b) ADA diabetes range HbA1c ( $\geq 6.5\%$ )

Separate meta-analyses were performed to assess the association between ADA pre-diabetes and diabetes HbA1c, and first-ever stroke risk. Risk ratio (RR, relative risk) data was treated as equivalent to hazard ratio data for analyses performed. Random-effects model meta-analyses were conducted to calculate the risk of first-ever stroke in pre-diabetes range HbA1c levels and diabetes-range HbA1c levels, using non-diabetes range HbA1c as the reference category (effect size= 1.0).

## Data S4:

---

### Linear regression analysis method for estimating continuous (1% HbA1c increment) effect size data from categorical effect size data

Continuous (1% HbA1c increment) effect size data was generated from studies presenting inter-categorical effect size data, using linear regression analysis. The linear regression method used is based upon the method described in Greenland [2], and used within Selvin [3] and Zhang [4].

The dataset was stratified into 4 subgroups based on a) ischaemic stroke subtype restriction and b) cohort diabetes status. Effect size data (HR or RR) extracted from the source studies corresponded to set categorical ranges of HbA1c within each source study. The categories of HbA1c presented within each study were assigned point values of HbA1c in order to facilitate their conversion into a continuous dataset. The point values of HbA1c assigned were selected in the following order; (1) study-quoted categorical **mean HbA1c value**, (2) study-quoted categorical **median value**, (3) normal distribution estimated categorical value.

Point measures of HbA1c assigned to each category of HbA1c within each study were then paired with the corresponding **log-transformed** effect size for their category of HbA1c, thereby creating a set of (x,y) co-ordinates for each study (where x= HbA1c point measure and y= log-transformed effect size).

Linear regression analyses were then performed using all available (x,y) datasets for each of the four dataset subgroups in order to test the validity of a linearity assumption (significance set at  $p < 0.05$ ).

Only 1 of the subgroup analyses failed to achieve statistical significance for a linear fit. Following two-way graph examination of this data set and given the statistical significance for linearity achieved in the remaining 3 dataset subgroups a linearity assumption was deemed appropriate for the overall association.

Separate linear regression analyses were conducted for each study's (x,y)=(HbA1c, log-effect size) data points in order to generate values for the linear coefficient ('a') and its 95% CI, where  $y = ax + c$ .

The linear coefficient ‘a’ represented the **log-transformed** 1% HbA1c increment effect size whilst its 95% CI represented the **log-transformed** 1% HbA1c increment effect size 95% CI.

Four studies [5-8] presented dichotomised HbA1c categorical data. As a result, linear regression analyses for these studies only provided a **log-transformed** 1% HbA1c increment effect size value but no 95% CI. The corresponding log-transformed 95% CI were estimated using the comparator (x,y) co-ordinate’s 95% CI as an estimate of overall statistical certainty, in lieu of linear regression calculated 95% CI.

The estimated 1% HbA1c increment log-transformed effect sizes (95% CI) within each of the four subgroups were then meta-analysed using a random-effects model in order to generate pooled effect sizes (95% CI) for each subgroup, as shown in **Supplementary Figure S11**.

Examples of linear regression assumption testing and linear regression log-transformed effect size (95% CI) method are shown in **Supplementary Figures S4-S5**.



**Supplementary Table S1: The association between rising HbA1c levels and stroke risk in adults without diabetes mellitus**

Author (citation) Country of origin (Year published)	Study cohort  Sample size (n' participants)	Age (in years)	Sex (% male)	Follow-up (in years)	Ethnicity description	Stroke temporality	Adjusted effect sizes (95% CI)	Covariates used in adjustment of adjusted effect sizes (95% CI) presented
Selvin [9] USA (2010)	ARIC  Total=11092	45-64 yo (ARIC)	42.30%	14 yrs (median)	'White'= 77.6% 'Black'= 22.4%	First-ever ischaemic stroke	<b>Hazard ratios (95% CI)</b> <b>Categorical HbA1c</b> 5.0 to <5.5%= reference <5.0%= 1.09 (0.68,1.77) 5.5 to <6.0%= 1.16 (0.89,1.53) 6.0 to <6.5%= 2.19 (1.58,3.05)* ≥6.5%= 2.96 (1.87, 4.67)* <b>1% HbA1c increments</b> = 1.55 (1.28,1.88)*	Age, sex, hypertension, HDL, LDL, log transformed TG, smoking status, BMI, WHR, ethnicity, family Hx DM, education status, alcohol consumption, physical activity, baseline FBG levels
Selvin [10] USA (2015)	ARIC  Total= 11104 Diabetes= 762 Non-diabetes=10342	45-64 yo (ARIC)	Total= 41.4%	Total= 20 yrs	Total: 'White'= 76.6% 'Black'= 23.4%	First-ever ischaemic stroke	<b>Hazard ratios (95% CI)</b> <b>Categorical HbA1c</b> 5.7 to 6.4%= reference <5.7%= 0.74 (0.61,0.91)* >6.4%= 1.79 (1.31, 2.45)*	Age, sex, systolic BP, HDL, LDL, TG, smoking status, BMI, WHR, ethnicity, anti-hypertensive medications, parental Hx of DM, education status, alcohol consumption, physical activity
Selvin [11] USA (2013)	ARIC  Total= 11077	45-64 yo (ARIC)	'White'= 44.3% 'Black'= 35.5%	Total= 18 yrs	'White'=77.58% 'Black'= 22.42%	First-ever stroke	<b>Hazard ratios (95% CI)</b> <b>Categorical HbA1c</b> <5.7%= reference 5.7% to <6.5%= 1.58 (1.23,2.03)*- 'white' 5.7% to <6.5%= 1.42 (1.02,1.97)*- 'black' ≥6.5%= 2.16 (1.38,3.37)*- 'white' ≥6.5%= 2.77 (1.81,4.23)*- 'black'	Age, sex, hypertension, HDL, LDL, log transformed TG, smoking status, BMI, WHR, family Hx DM, education status, alcohol use, physical activity
Karas [5] USA (2012)	Strong Heart Study  Total= 2391	45-74 yo	Stroke patients = 43.3%  Non-stroke patients = 45.5%	12 yrs (mean)	American Indians	First-ever ischaemic stroke	<b>Hazard ratios (95% CI)</b> <b>Categorical HbA1c</b> <6.5%= reference ≥6.5%= 1.50 (0.90, 2.51) <b>1 SD HbA1c increments</b> =1.47 (1.21,1.78)* {1 SD= 1.4%}	Age, sex, systolic BP, HDL, LDL, smoking status, BMI, anti-hypertensive medications, diabetes status, serum creatinine, UACR, LA diameter, mitral annular calcification, HbA1c
Wang [12] USA (2011)	Strong Heart Study  Total= 3850 Diabetes= 1386 Non-diabetes= 2464	45-74 yo	40%	15 yrs (median)	American Indians	First-ever stroke	<b>Hazard ratios (95% CI)</b> <b>Categorical HbA1c</b> <5.0%= reference 5.0 to <5.5%= 1.09 (0.68,1.74) 5.5 to <6.0%= 1.60 (1.00,2.57) 6.0 to <6.5%= 1.24 (0.61,2.53) ≥6.5%= 1.93 (1.06, 3.52)*	Age, sex, hypertension, systolic BP, HDL, LDL, smoking status, log urinary albumin:creatinine ratio, baseline FBG levels
Birkenhager-Gillesse [13] Netherlands (2015)	Leiden 85+ Study  Total= 445	85-95 yo	35%	Total for fatal events = 10 yrs  Total for non-fatal events = 5 yrs	Inhabitants of Leiden, Netherlands	First-ever stroke	<b>Hazard ratios (95% CI)</b> <b>Categorical HbA1c</b> 5.0 to 5.7%= reference <5.0%= 1.0 (0.4,2.8) 5.7 to 6.5%= 0.9 (0.4,2.0) <b>HbA1c ~1% increments</b> = 0.9 (0.5, 1.6)	Sex, systolic BP, total cholesterol, smoking status, BMI, AMI, stroke, cardiovascular disease at baseline (cardiac surgery, AMI, stroke), education status, living conditions, income, creatinine clearance, c-reactive protein, alcohol consumption

Supplementary Table S1 (continued)...

Author (citation) Country of origin (Year published)	Study cohort Sample size (n' participants)	Age (in years)	Sex (% male)	Follow-up (in years)	Ethnicity description	Stroke temporality	Adjusted effect sizes (95% CI)	Covariates used in adjustment of adjusted effect sizes (95% CI) presented
Lawlor [14] UK (2007)	The British Women's Heart and Health Total= 3246	60-79 yo	0%	4.6 yrs (median)	British women, >99% 'white'	First-ever stroke	<b>Hazard ratios (95% CI)</b> <u>1 SD HbA1c increments</u> = 1.02 (0.79,1.33) {1 SD= 0.83%}	Age, systolic BP, HDL, TG, LDL, smoking status, BMI, WHR, physical activity, socioeconomic status
Chen [15] Taiwan (2015)	Taiwan's Triple High Survey Total= 5277 Non-diabetes=4915 Diabetes= 362	≥18 yo	Non-diabetes patients = 46.5%	Total= 9.7 yrs (9.6-9.74) (median [IQR])	Taiwanese residents	First-ever stroke	<b>Hazard ratios (95% CI)</b> <u>1% HbA1c increments</u> = 1.34 (0.85,1.51)	Age, sex, systolic BP, TG, HDL, waist circumference, anti-hypertensives, lipid-lowering agents, anti-platelet drugs, anti-acid agents, family history of stroke, uric acid, creatinine
Goto [16] Japan (2015)	Japan Public Healthcare Study Total=29059 Non-diabetes=27279	40-69 yo	<u>Stratified by HbA1c:</u> <5.0%= 43.2% 5.0 to 5.4%= 36.3% 5.5 to 5.9%= 34.5% 6.0 to 6.4%= 39.5% ≥6.5%= 47.6%	9.4 yrs (median)	Japanese residents	First-ever stroke	<b>Hazard ratios (95% CI)</b> <u>Categorical HbA1c</u> 5.0 to 5.4%= reference <5.0%= 1.55 (1.17,2.05)* 5.5 to 5.9%= 0.99 (0.82,1.20) 6.0 to 6.4%= 0.97 (0.74, 1.26) ≥6.5%= 1.80 (1.30,2.50)*	Age, sex, systolic BP, non-HDL, HDL, smoking status, BMI, public health centre area, physical activity, alcohol consumption
Chonchol [17] USA (2010)	Cardiovascular Health Study Total=810	≥65 yo	41%	14.2 yrs (median)	'Black' participants <u>by HbA1c %:</u> ≤5.6%= 4% 5.61-6.20%= 6% ≥6.21%= 9%	First-ever stroke	<b>Hazard ratios (95% CI)</b> <u>Categorical HbA1c</u> ≤5.6%= reference 5.61 to 6.20%= 0.87 (0.54, 1.39) ≥6.21%= 1.08 (0.69, 1.70)	Age, gender, hypertension, LDL, smoking status, BMI, ethnicity, chronic kidney disease
Ikeda [18] Japan (2013)	Hisayama study Diabetes= 237 Non-diabetes=2614 Total= 2851	40-79 yo	<u>Stratified by HbA1c:</u> ≤5.0%= 46% 5.1 to 5.4%= 38.1% 5.5 to 6.4%= 41.9%	Total= 7 yrs	Japanese residents	First-ever ischaemic stroke	<b>Hazard ratios (95% CI)</b> <u>Categorical HbA1c</u> ≤5.0%= reference 5.1 to 5.4%= 2.57 (0.91,7.29) 5.5 to 6.4%= 3.57 (1.27,10.0)*	Age, sex, hypertension, total cholesterol, HDL, smoking status, BMI, alcohol consumption, physical activity, ECG abnormalities
Myint [19] UK (2007)	EPIC-Norfolk Total= 10489	40-79 yo	<u>Stratified by HbA1c:</u> <5%= 42% 5 to 5.4%= 45% 5.5 to 6.9%= 46% ≥7.0%= 56%	8.5 yrs (mean)	British 99.6% 'white'	First-ever stroke	<b>Relative risk (95% CI)</b> <u>Categorical HbA1c</u> <5.0%= reference 5.0 to 5.4%= 0.78 (0.50, 1.22) 5.5 to 6.9%= 0.83 (0.54,1.27) ≥7.0%= 2.83 (1.40, 5.74)*	Age, sex, systolic BP, total cholesterol, TG, smoking status, BMI, AMI at baseline, alcohol consumption
Wu [20] China (2013)	ACROSS-China Total= 2186 Subgroup used =1540	Adults (mean age +/- SD = 64 +/- 11 yo in recurrent stroke patients, 61 +/- 12 yo in non stroke patients) <b>at 1 year</b>	Stroke patients = 54.2% Non-stroke patients = 62.3% <b>at 1 year</b>	Total= 1 yr	Chinese cohort	Recurrent stroke	<b>Hazard ratios (95% CI)</b> <u>Categorical HbA1c</u> <5.5%= reference 5.5 to <6.1%= 1.06 (0.35,3.23) 6.1 to <7.2%= 3.08 (1.10,8.64)* ≥7.2%= 3.31 (1.35,8.14)*	Age, gender, systolic and diastolic BP, HDL, LDL, TG, cholesterol, smoking status, BMI, waist circumference, coronary heart disease, hypertension, family Hx stroke, history of DM, ischemic stroke subtypes, OCSP subtypes, HOMA, antithrombotic agents, antihypertensive medications, lipid lowering medications, medication adherence, educational status, alcohol consumption, uric acid, homocysteine, creatinine, FBG

Results presented represent the most adjusted hazard ratios (HR) or risk ratios (RR, relative risk) available in the source literature. Results presented only apply to participants without diabetes mellitus within the source study. Covariates listed are those used in adjustment of results quoted. Where available, both continuous and categorical HR or RR data was included for each study. Statistically significant results are identified with \*. Continuous results described as '1 SD' represent 1 standard deviation increment elevations in HbA1c. The SD value is shown in brackets provided. The descriptor 'stroke temporality' refers to the type of stroke outcome measured in the results presented for each study. DM= diabetes mellitus, CVD= cardiovascular disease, BP= blood pressure, LDL= low density lipoprotein, HDL= high density lipoprotein, TG= triglyceride, BMI= body mass index, WHR= waist-hip ratio, UACR= urinary albumin-creatinine ratio, FBG= fasting blood glucose, AMI= acute myocardial infarction, OCSP= Oxfordshire Community Stroke Project, HOMA= Homeostasis Model Assessment, LA= left atrium, ECG= electrocardiograph, Hx= history, yo= years old, IQR= interquartile range, yrs= years.

**Supplementary Table S2: The association between rising HbA1c levels and stroke risk in adults with T1DM**

Author (citation) Country of origin (Year published)	Study cohort Sample size (n' participants)	Age (in years)	Sex (% male)	Follow-up (in years)	Ethnicity description	Stroke temporality	Adjusted effect sizes (95% CI)	Covariates used in adjustment of adjusted effect sizes (95% CI) presented
<b>Stahl [21]</b> Sweden (2016)	Swedish NDR Total= 33453	≥18 yo	55% in T1DM cohort	7.9 +/- 4.3 yrs (mean +/- SD)	Swedish diabetes patients	First-ever stroke	<b>Hazard ratios (95% CI)</b> <u>Categorical HbA1c</u> ≤6.9%= reference 7.0 to 7.8%= 1.30 (0.96,1.76) 7.9 to 8.7%= 1.96 (1.47,2.63)* 8.8 to 9.6%= 2.25 (1.64,3.08)* ≥9.7%= 3.61 (2.56,5.08)*	Age, sex, duration of DM, systolic BP, smoking status, BMI, atrial fibrillation, coronary heart disease, education status
<b>Eeg-Olofsson [22]</b> Sweden (2010)	Swedish NDR Total= 7454	20-65 yo	55.80%	4.95 yrs (mean)	Swedish diabetes patients	First-ever stroke	<b>Hazard ratios (95% CI)</b> <u>Categorical HbA1c</u> 5.0 to 7.9%= reference 8.0 to 11.9%= 1.40 (0.70,2.79) <u>1% HbA1c increments</u> = 1.19 (0.86,1.66)	Age, sex, duration of DM, systolic BP, smoking status, BMI, total cholesterol, LDL, TG, history of CVD, albuminuria (>20 microg/min)
<b>Hagg [23]</b> Finland (2014)	FinnDiane Total= 4083	Adult mean age +/- SD = 37.4 +/- 11.8 yo	51.00%	9.0 +/- 2.7 yrs (mean +/- SD)	FinnDiane participants	First-ever stroke	<b>Hazard ratios (95% CI)</b> <u>~1% HbA1c increments</u> = 1.16 (1.03,1.31)*	Sex, duration of DM, systolic and diastolic BP, TG, LDL, HDL, smoking status, waist circumference, coronary heart disease, diabetic nephropathy, severe diabetic retinopathy, anti-hypertensive medications, lipid lowering medications, aspirin

Results presented represent the most adjusted hazard ratios (HR) or risk ratios (RR, relative risk) available in the source literature. Results presented only apply to participants with T1DM within the source study. Covariates listed are those used in adjustment of results quoted. Where available, both continuous and categorical HR or RR data was included for each study. Statistically significant results are identified with \*. The descriptor 'stroke temporality' refers to the type of stroke outcome measured in the results presented for each study. T1DM= type 1 diabetes mellitus, CVD= cardiovascular disease, BP= blood pressure, BMI= body mass index, WHR= waist-hip ratio, TG= triglyceride, HDL= high density lipoprotein, LDL= low density lipoprotein, DM= diabetes mellitus, yo= years old, SD= standard deviation, yrs= years.

**Supplementary Table S3: The association between rising HbA1c levels and stroke risk in adults with T2DM**

Author (citation) Country of origin (Year published)	Study cohort Sample size (n' participants)	Age (in years)	Sex (% male)	Follow-up (in years)	Ethnicity description	Stroke temporality	Adjusted effect sizes (95% CI)	Covariates used in adjustment of adjusted effect sizes (95% CI) presented
<b>Adler [24]</b> UK (1999)	UKPDS 47  Total= 5102 For stroke analysis= 3670	25-65 yo	59%	10.3 yrs (median)	White caucasian= 83% Asian/Indian= 10% Afro-caribbean= 8%	First-ever stroke	<u>Hazard ratios (95% CI)</u> <u>Categorical HbA1c</u> ≤6.3%= reference >6.3 to ≤7.6 %= 1.2 (0.8,1.7) >7.6%= 1.1 (0.7,1.6)	Age, sex, diastolic BP only, total cholesterol, TG, HDL, smoking status, BMI, ethnicity, stroke history, physical activity, social class
<b>Skriver [6]</b> Denmark (2012)	Aarhus County Public data files  Total=17760  For stroke analysis= 11747	Adult  <u>Median (IQR) age by HbA1c level:</u> 67 (57-77) yo= <7% 65 (56-74) yo= ≥7%	<u>Stratified by HbA1c:</u> <7%= 50.4% ≥7%= 53.9%	2 yrs (median)	Danish residents	First-ever stroke	<u>Hazard ratios (95% CI)</u> <u>Categorical HbA1c</u> <7.0%= reference ≥7.0%= 1.00 (0.78,1.27)	Age, sex, duration of DM, prior hospital admission for CVD- (myocardial infarction, congestive heart failure, peripheral vascular disease and cerebrovascular disease represented prior cardiovascular disease) Non-cardiovascular diseases including; dementia, chronic pulmonary disease, connective tissue disease, ulcer disease, mild liver disease, hemiplegia, moderate to severe renal disease, diabetes with end-organ damage, any tumour, leukaemia, lymphoma, moderate or severe liver disease, metastatic solid tumour and AIDS
<b>Kontopantelis [25]</b> UK (2014)	UK CPRD  Total= 246544	≥18 yo	Stratified based on year of inclusion in the study	Total= 6 yrs	English, Northern Irish, Welsh and Scottish participants	First-ever stroke	<u>Hazard ratios (95% CI)</u> <u>Categorical HbA1c</u> ≥6.25 to ≤6.75%= reference <6.25%= 1.169 (0.979,1.396) >6.75 to ≤7.25%= 1.084 (0.892,1.318) >7.25 to ≤7.75%= 1.205 (0.976,1.487) >7.75 to ≤8.25%= 1.366 (1.079,1.730)* >8.25%= 1.314 (1.072,1.611)*	Age, sex, systolic and diastolic BP, cholesterol, smoking status, BMI, history of macrovascular complications- (PVD, AMI, stroke, amputation), history of microvascular complications- (retinopathy, neuropathy, nephropathy, foot ulcer, CKD stage 4-5, foot ulcer), practice characteristics (diabetes prevalence, list size, region, area deprivation)
<b>Freemantle [26]</b> Multinational (EU, North America, Asia) (2016)	CREDIT  Total=2999	>40 yo	51.20%	4.2 (3.5 - 4.4) yrs (median [IQR])	<u>Median % from region:</u> 24.5% North America 21.6% Eastern Europe 15.3% Southern Europe 17.0% France 8.4% Northern Europe 13.1% Japan	First-ever stroke	<u>Hazard ratios (95% CI)</u> <u>1% HbA1c increments</u> = 1.363 (1.168,1.591)*	Age, hypertension, history or presence of macrovascular disease
<b>Kranenburg [27]</b> Netherlands (2015)	SMART study  Total= 1687 Hx CVD= 1156 No Hx CVD= 531	18-80 yo	No vascular disease group = 59.0%	6.1 (3.1 - 9.5) yrs (median [IQR])	Patients referred to the medical centre Utrecht	First-ever <b>ischaemic</b> stroke	<u>Hazard ratios (95% CI)</u> <u>1% HbA1c increments</u> = 1.40 (1.01,1.94)*	Age, sex, duration of DM, systolic BP, smoking status, non-HDL level, modification of diet in renal disease
<b>Lin [28]</b> Taiwan (2014)	National Diabetes Care Management Program  Total= 28354	≥30 yo	<u>Stratified by HbA1c:</u> <7.0%= 52.31% ≥7.0%= 45.22%	7.5 yrs (mean)	Ethnically Chinese participants	First-ever <b>ischaemic</b> stroke	<u>Hazard ratios (95% CI)</u> <u>Categorical HbA1c</u> <7.0%= reference 7.0 to 8.0%= 1.27 (1.13,1.43)* 8.0 to 9.0%= 1.55 (1.37,1.75)* ≥9.0%= 2.06 (1.85,2.31)*	Age and gender only

Supplementary Table S3 (continued)...

Author (citation) Country of origin (Year published)	Study cohort  Sample size (n' participants)	Age (in years)	Sex (% male)	Follow-up (in years)	Ethnicity description	Stroke temporality	Adjusted effect sizes (95% CI)	Covariates used in adjustment of adjusted effect sizes (95% CI) presented
<b>Kong [7]</b> China (2007)	Prince of Wales Hospital (Hong Kong)  Total= 6386	Adult median (IQR) age =56 (46-67) yo	Stratified by number of treatment goals achieved	5.7 yrs (median)	Patients attending the Prince of Wales Hospital (Hong Kong)	First-ever stroke	<b>Hazard ratios (95% CI)</b> <b>Categorical HbA1c</b> ≥7.0%= reference <7.0%= 0.76 (0.58,0.99)*	Age and sex only
<b>Zhao [29]</b> USA (2014)	LSU Health Care Services Division  Total=30154 Male= 9783 Female= 17422	Adult <u>Mean +/- SD age by gender:</u> male= 50.9 +/- 10.1 yo female= 51.48 +/- 10.1 yo	36.07%	6.7 yrs (mean)	African American (total): - Males= 56.1% - Females= 59.3%	First-ever stroke	<b>Hazard ratios (95% CI)</b> <b>Categorical HbA1c</b> 6.0 to 6.9%= reference <u>&lt;6.0%:</u> male= 1.05 (0.88,1.26), female= 1.06 (0.93,1.21) <u>7.0 to 7.9%:</u> male= 1.12 (0.94,1.33), female= 1.11 (0.97,1.27) <u>8.0 to 8.9%:</u> male= 1.20 (0.98,1.46), female= 1.30 (1.12,1.52)* <u>9.0 to 9.9%:</u> male= 1.23 (0.98,1.54), female= 1.41 (1.19,1.68)* <u>≥10.0%:</u> male= 1.08 (0.86,1.36), female= 1.33 (1.11,1.59)*  <u>1% HbA1c increments (male participants)</u> = 1.02 (0.98,1.05) <u>1% HbA1c increments (female participants)</u> = 1.06 (1.03,1.09)*	Age only
<b>Cederholm [8]</b> Sweden (2009)	Swedish NDR  Total= 4753	30-70 yo	Stratified by BP and HbA1c groups	5.7 yrs (mean)	Swedish diabetes patients	First-ever stroke	<b>Hazard ratios (95% CI)</b> <b>Categorical HbA1c</b> 7.5 to 9.0% (BP:141-190/91-110)= reference <7.5% (BP ≤140/90)= 0.47 (0.36,0.63)*	Age and sex only
<b>Giorda [30]</b> Italy (2007)	DAI study  Total= 14432 For stroke analysis = 11644	40-97 yo	48.20%	Total= 4 yrs	Italian cohort	First-ever stroke	<b>Hazard ratios (95% CI)</b> <u>1% HbA1c increments</u> Male participants= 1.27 (1.11,1.46)* Female participants= 1.07 (0.92,1.26)	Age only
<b>Elley [31]</b> New Zealand (2008)	Multicentre New Zealand cohort  Total= 48444	Adult median age = 60 yo	49%	2.4 yrs (median)	49% European ethnicity	First-ever stroke	<b>Hazard ratios (95% CI)</b> <u>1% HbA1c increments</u> = 1.09 (1.04,1.13)*	Age, gender, duration of DM, systolic BP, total cholesterol:HDL ratio, smoking status, BMI, ethnicity, socio-economic status, urine albumin:creatinine ratio
<b>Camafort [32]</b> Spain (2011)	FRENA study  Total= 974	Adult mean +/- SD age = 69 +/- 9 yo	59% (in stroke positive patients)	1.17 yrs (mean)	Patients attending FRENA study hospitals	<b>Ischaemic stroke</b> (first-ever and recurrent events)	<b>Relative risk (95% CI)</b> <b>Categorical HbA1c</b> ≥7.0%= reference <7.0%= 0.9 (0.4,1.9)	Age, gender, systolic BP, use of drugs, creatinine clearance levels, clinical presentation
<b>Bots [33]</b> Netherlands (2016)	SMART study  Total= 1096	18-79 yo	76%	Total= 6.9 yrs for mortality and 6.4 yrs for vascular events	Patients referred to the medical centre Utrecht	<b>Ischaemic stroke</b> (first-ever and recurrent events)	<b>Hazard ratios (95% CI)</b> <u>1% HbA1c increments</u> = 1.09 (0.84,1.41)	Age, sex, duration of DM, systolic BP, non-HDL cholesterol, smoking status, eGFR (MDRD)
<b>Hayashi [34]</b> Japan (2013)	JCDM  Total= 4014	Adult mean +/- SD age = 67.9 +/- 2.0 yo	Mean= 51.2%	Total= 5.5 yrs	Japanese participants	Stroke (first-ever and recurrent events)	<b>Hazard ratios (95% CI)</b> <u>1% HbA1c increments</u> = 1.001 (0.790,1.214)	Age, gender, duration of DM, systolic + diastolic BP, TG, LDL, HDL, FBG level

Results presented represent the most adjusted hazard ratios (HR) or risk ratios (RR, relative risk) available in the source literature. Results presented only apply to participants with T2DM within the source study. Covariates listed are those used in adjustment of results quoted. Results adjusted for hypoglycemic medication use were not selected. In these instances, the next most adjusted result(s) were selected. Where available, both continuous and categorical HR or RR data was included for each study. Statistically significant results are identified with \*. The descriptor 'stroke temporality' refers to the type of stroke outcome measured in the results presented for each study. T2DM= type 2 diabetes mellitus, CVD= cardiovascular disease, BP= blood pressure, LDL= low density lipoprotein, HDL= high density lipoprotein, TG= triglyceride, BMI= body mass index, WHR= waist-hip ratio, AIDS= Autoimmune Deficiency Syndrome, PVD= peripheral vascular disease, AMI= acute myocardial infarction, CKD= chronic kidney disease, eGFR (MDRD)= MDRD derived eGFR, FBG= fasting blood glucose, SD= standard deviation, IQR= interquartile range, yo= years old, yrs= years, Hx= history.

**Supplementary Table S4: The association between rising HbA1c levels and stroke risk in mixed diabetes cohorts**

Author (citation) Country of origin (Year published)	Study cohort  Sample size (n' participants)	Age (in years)	Sex (% male)	Follow-up (in years)	Ethnicity description	Stroke temporality	Adjusted effect sizes (95% CI)	Covariates used in adjustment of adjusted effect sizes (95% CI) presented
<b>Xu [35]</b> China (2012)	Hong Kong EHS  Total= 2137	≥65 yo	Gender by HbA1c % level: <6.5%= 40% 6.5 to 7.4%= 32.9% 7.5 to 8.4%= 32.7% >8.5%= 37.3%	7.9 yrs (mean)	Hong Kong residents involved in the EHS	First-ever stroke	<b>Hazard ratios (95% CI)</b> <b>Categorical HbA1c</b> 7.5 to 8.4%= reference <6.5%= 2.12 (0.85,5.31) 6.5 to 7.4%= 1.49 (0.64,3.49) ≥8.5%= 2.43 (1.06,5.55)*  <b>1% HbA1c increments:</b> <b>4.4 to 6.4% HbA1c:</b> 0.49 (0.26,0.95)* <b>6.5 to 15.5% HbA1c:</b> 1.30 (1.01,1.68)*	Age, sex, mean arterial pressure, total cholesterol, smoking status, BMI, history of CVD- (defined as self-reported physician-diagnosed ischaemic heart disease, circulatory disease or peripheral vascular disease), alcohol consumption, exercise, educational status
<b>Moss [36]</b> USA (1994)	WESDR  Total= 2366 Cohort for outcomes assessed= 1265	≥30 yo	45.6% (in cohort of interest)	8.3 yrs (median) (in cohort of interest)	98.6% 'white'	First-ever stroke	<b>Hazard ratios (95% CI)</b> <b>1% HbA1c increments</b> = 1.17 (1.05,1.30)*	Age, sex, hypertension, history of CVD
<b>Chen [15]</b> Taiwan (2015)	Taiwan's Triple High Survey  Total= 5277 Non-diabetes= 4915 Diabetes= 362	≥18 yo	Diabetes patients = 50.8%	9.7 yrs (9.6-9.74) (median [IQR])	Taiwanese residents	First-ever stroke	<b>Hazard ratios (95% CI)</b> <b>1% HbA1c increments</b> = 1.22 (1.04,1.44)*	Age, sex, systolic BP, TG, HDL, waist circumference, family history of stroke, uric acid, creatinine
<b>Selvin [37]</b> USA (2005)	ARIC  Total= 2482 Diabetes= 1635	45-64 yo	Not detailed	9 yrs (mean)	Not detailed	First-ever ischaemic stroke	<b>Relative risk (95% CI)</b> <b>Categorical HbA1c</b> Cat.1 (median=5.0%)= reference Cat. 2(median=6.0%)= 1.17 (0.62,2.19) Cat. 3(median= 9.0%)= 2.33 (1.29,4.21)*	Age, sex, systolic and diastolic BP,HDL, LDL, smoking status, BMI, WHR, ethnicity, anti-hypertensive medication,educational status
<b>Alter [38]</b> USA (1997)	Lehigh Valley Stroke Cohort  Total= 621 Non-diabetes= 423 Diabetes= 198	Adult diabetes mean +/- SD= 70 +/- 10.8 yo	47.5% in diabetes subgroup, 51.4% overall	2 yrs (mean)	95%= 'white' 1.7%= 'black' 3.3%= 'hispanic'	Recurrent stroke	<b>Hazard ratios (95% CI)</b> <b>1% HbA1c increments</b> = 0.87 (0.623,1.219)	Age, sex, hypertension, AMI, cardiac arrhythmia, TIA
<b>Ashburner [39]</b> USA (2016)	ATRIA  Total= 2101 people with diabetes	≥18 yo	<b>Stratified by HbA1c:</b> <7%= 63.2% 7.0 to 8.9%= 60.4% ≥9.0%= 57.5%	2.48 +/- 2.23 yrs (mean +/- SD)	<b>&lt;7%:</b> White=86.5%, Black=3.5%, Other=0.7%, Asian/Pacific Islander=6.2%, Hispanic=3.1%  <b>7.0-8.9%:</b> White=85.7% Black=5.1%, Other=0.6% Asian/Pacific Islander=6.4%, Hispanic=2.2%  <b>≥9.0%:</b> White=78.6%, Black=7.8%, Other=0.8% Asian/Pacific Islander=9.2%, Hispanic=3.9%	<b>Ischaemic stroke</b> (first- ever and recurrent events)	<b>Hazard ratios (95% CI)</b> <b>Categorical HbA1c</b> <7.0%= reference 7.0 to 8.9%= 1.09 (0.75,1.60) >9.0%= 1.10 (0.70, 1.72)	<b>Unadjusted result</b> used as adjusted result includes adjustment for insulin use
<b>Hirai [40]</b> USA (2008)	WESDR  Total= 1370 Subgroup used = 1007	≥30 yo	44.90%	Total= 16 yrs	Wisconsin residents	Stroke (first-ever and recurrent events)	<b>Hazard ratios (95% CI)</b> <b>1% HbA1c increments</b> = 1.08 (0.98,1.18)	Age and sex only

Results presented represent the most adjusted hazard ratios (HR) or risk ratios (RR, relative risk) available in the source literature. Results presented only apply to participants with diabetes mellitus (T1DM, T2DM or unspecified type) in the source study. Mixed diabetes participants include T1DM, T2DM and/or unspecified diabetes type. Covariates listed are those used in adjustment of results quoted. Results adjusted for hypoglycemic medication use were not selected. In these instances, the next most adjusted result(s) were selected. Where available, both continuous and categorical HR or RR data was included for each study. Statistically significant results are identified with \*. The descriptor 'stroke temporality' refers to the type of stroke outcome measured in the results presented for each study. T1DM= type 1 diabetes mellitus, T2DM= type 2 diabetes mellitus, CVD= cardiovascular disease, BMI= body mass index, BP= blood pressure, TG= triglyceride, LDL= low density lipoprotein, HDL= high density lipoprotein, WHR= waist-hip ratio, TIA= transient ischaemic attack, AMI= acute myocardial infarction, SD= standard deviation, IQR= interquartile range, yo= years old, yrs= years.

**Supplementary Table S5: Association between rising HbA1c levels and ischaemic stroke risk, in adults without diabetes mellitus**

Author (citation) Country of origin (Year published)	Study cohort Sample size (n' participants)	Age (in years)	Sex (% male)	Follow-up (in years)	Ethnicity description	Diabetes status of participants assessed	Adjusted effect sizes (95% CI)	Covariates used in adjustment of adjusted effect sizes (95% CI) presented
<b>Selvin [9]</b> USA (2010)	ARIC Total=11092	45-64 yo (ARIC)	42.30%	14 yrs (median)	'White'= 77.6% 'Black'= 22.4%	Non-diabetes	<b>Hazard ratios (95% CI)</b> <b>Categorical HbA1c</b> 5.0 to <5.5%= reference <5.0%= 1.09 (0.68,1.77) 5.5 to <6.0%= 1.16 (0.89,1.53) 6.0 to <6.5%= 2.19 (1.58,3.05)* ≥6.5%= 2.96 (1.87, 4.67)* <b>1% HbA1c increments</b> = 1.55 (1.28,1.88)*	Age, sex, hypertension, HDL, LDL, log transformed TG, smoking status, BMI, WHR, ethnicity, family Hx DM, education status, alcohol consumption, physical activity, baseline FBG levels
<b>Selvin [10]</b> USA (2015)	ARIC Total= 11104 Diabetes= 762 Non-diabetes=10342	45-64 yo (ARIC)	41.40%	Total= 20 yrs	'White'= 76.6% 'Black'= 23.4%	Non-diabetes	<b>Hazard ratios (95% CI)</b> <b>Categorical HbA1c</b> 5.7 to 6.4%= reference <5.7%= 0.74 (0.61,0.91)* >6.4%= 1.79 (1.31, 2.45)*	Age, sex, systolic BP, HDL, LDL, TG, smoking status, BMI, WHR, ethnicity, anti-hypertensive medications, parental Hx of DM, education status, alcohol consumption, physical activity
<b>Selvin [11]</b> USA (2013)	ARIC Total= 11077	45-64 yo (ARIC)	'White'= 44.3% 'Black'= 35.5%	Total= 18 yrs	'White'=77.58% 'Black'= 22.42%	Non-diabetes	<b>Hazard ratios (95% CI)</b> <b>Categorical HbA1c</b> <5.7%= reference 5.7% to <6.5%= 1.50 (1.14,1.97)*- 'white' 5.7% to <6.5%= 1.38 (0.97,1.96)- 'black' ≥6.5%= 2.13 (1.34,3.41)*- 'white' ≥6.5%= 2.80 (1.79,4.38)*- 'black'	Age, sex, hypertension, HDL, LDL, log transformed TG, smoking status, BMI, WHR, family Hx DM, education status, alcohol use, physical activity
<b>Karas [5]</b> USA (2012)	Strong Heart Study Total= 2391	45-74 yo	Stroke patients = 43.3% Non-stroke patients = 45.5%	12 yrs (mean)	American Indians	Non-diabetes	<b>Hazard ratios (95% CI)</b> <b>Categorical HbA1c</b> <6.5%= reference ≥6.5%= 1.50 (0.90, 2.51) <b>1 SD HbA1c increments</b> =1.47 (1.21,1.78)* (1 SD= 1.4%)	Age, sex, systolic BP, HDL, LDL, smoking status, BMI, anti-hypertensive medications, diabetes status, serum creatinine, UACR, LA diameter, mitral annular calcification, HbA1c
<b>Chen [15]</b> Taiwan (2015)	Taiwan's Triple High Survey Total= 5277 Non-diabetes=4915 Diabetes= 362	≥18 yo	Non-diabetes = 46.5%	Total (median [IQR]) =9.7 yrs (9.6-9.74)	Taiwanese residents	Non-diabetes	<b>Hazard ratios (95% CI)</b> <b>1% HbA1c increments</b> =1.40 (1.04,1.87)*	Age, sex, systolic BP, TG, HDL, waist circumference, anti-hypertensives, lipid-lowering agents, anti-platelet drugs, anti-acid agents, family history of stroke, uric acid, creatinine
<b>Goto [16]</b> Japan (2015)	Japan Public Healthcare Study Total=29059 Non-diabetes =27279	40-69 yo	<b>Stratified by HbA1c:</b> <5.0%= 43.2% 5 to 5.4%= 36.3% 5.5 to 5.9%= 34.5% 6.0 to 6.4%= 39.5% ≥6.5%= 47.6%	9.4 yrs (median)	Japanese residents	Non-diabetes	<b>Hazard ratios (95% CI)</b> <b>Categorical HbA1c</b> 5.0 to 5.4%= reference <5.0%= 1.47 (0.996,2.15) 5.5 to 5.9%= 1.00 (0.78,1.29) 6.0 to 6.4%= 1.06 (0.75,1.51) ≥6.5%= 2.29 (1.53,3.42)*	Age, sex, systolic BP, non-HDL, HDL, smoking status, BMI, public health centre area, physical activity, alcohol consumption
<b>Ikeda [18]</b> Japan (2013)	Hisayama study Diabetes= 237 Non-diabetes=2614 Total= 2851	40-79 yo	<b>Stratified by HbA1c:</b> ≤5.0%= 46% 5.1 to 5.4%= 38.1% 5.5 to 6.4%= 41.9% ≥6.5%= 47.1%	Total= 7 yrs	Japanese residents	Non-diabetes	<b>Hazard ratios (95% CI)</b> <b>Categorical HbA1c</b> ≤5.0%= reference 5.1 to 5.4%= 2.57 (0.91,7.29) 5.5 to 6.4%= 3.57 (1.27,10.0)*	Age, sex, hypertension, total cholesterol, HDL, smoking status, BMI, alcohol consumption, physical activity, ECG abnormalities

Results presented represent the most adjusted hazard ratios (HR) or risk ratios (RR, relative risk) available in the source literature. Results presented only apply to participants without diabetes mellitus within the source study. Covariates listed are those used in adjustment of results quoted. Where available, both continuous and categorical HR or RR data was included for each study. Statistically significant results are identified with \*. Continuous results described as '1 SD' represent 1 standard deviation increment elevations in HbA1c. The SD value is shown in brackets provided. HDL= high density lipoprotein, LDL= low density lipoprotein, TG= triglyceride, BMI= body mass index, WHR= waist-hip ratio, DM= diabetes mellitus, FBG= fasting blood glucose, UACR= urinary albumin creatinine ratio, LA= left atrial, ECG= electrocardiograph, IQR= interquartile range, yrs= years, yo= years old, Hx= history.

**Supplementary Table S6: Association between rising HbA1c levels and ischaemic stroke risk, in adults with diabetes mellitus**

Author (citation) Country of origin (Year published)	Study cohort  Sample size (*n' participants)	Age (in years)	Sex (% male)	Follow-up (in years)	Ethnicity description	Diabetes status of participants assessed	Adjusted effect sizes (95% CI)	Covariates used in adjustment of adjusted effect sizes (95% CI) presented
Hagg [23] Finland (2014)	FinnDiane  Total= 4083	Adult mean age +/- SD = 37.4 +/- 11.8 yo	51.00%	9.0 +/- 2.7 yrs (mean +/- SD)	FinnDiane participants	T1DM	<b>Hazard ratios (95% CI)</b>  <u>~1% HbA1c increments</u> = 1.21 (1.05,1.40)*	Sex, duration of DM, systolic and diastolic BP, TG, LDL, HDL, smoking status, waist circumference, coronary heart disease, diabetic nephropathy, severe diabetic retinopathy, anti-hypertensive medications, lipid lowering medications, aspirin
Chen [15] Taiwan (2015)	Taiwan's Triple High Survey  Total= 5277 Non-diabetes= 4915 Diabetes= 362	≥18 yo	Diabetes patients = 50.8%	9.7 yrs (9.6-9.74) (median [IQR])	Taiwanese residents	Mixed diabetes cohort	<b>Hazard ratios (95% CI)</b>  <u>1% HbA1c increments</u> = 1.25 (1.01,1.54)*	Age, sex, systolic BP, TG, HDL, waist circumference, family history of stroke, uric acid, creatinine
Selvin [37] USA (2005)	ARIC  Total= 2482 Diabetes= 1635	45-64 yo	Not detailed	9 yrs (mean)	Not detailed	Mixed diabetes cohort	<b>Relative risk (95% CI)</b>  <u>Categorical HbA1c</u> Category 1 (median=5.0%)= reference Category 2 (median=6.0%) = 1.17 (0.62,2.19) Category 3 (median= 9.0%) = 2.33 (1.29,4.21)*	Age, sex, systolic and diastolic BP, HDL, LDL, smoking status, BMI, WHR, ethnicity, anti-hypertensive medication, educational status
Stahl [21] Sweden (2016)	Swedish NDR  Total= 33453	≥18 yo	55% in T1DM cohort	7.9 +/- 4.3 yrs (mean +/- SD)	Swedish diabetes patients	T1DM	<b>Hazard ratios (95% CI)</b> <u>Categorical HbA1c</u> ≤6.9% = reference 7.0 to 7.8%= 1.20 (0.87,1.66) 7.9 to 8.7%= 1.92 (1.41,2.60)* 8.8 to 9.6%= 2.09 (1.50,2.92)* ≥9.7%= 3.27 (2.27,4.71)*	Age, sex, duration of DM, systolic BP, smoking status, BMI, atrial fibrillation, coronary heart disease, education status
Bots [33] Netherlands (2016)	SMART study  Total= 1096	18-79 yo	76%	Total= 6.9 yrs for mortality and 6.4 yrs for vascular events	Patients referred to the medical centre Utrecht	T2DM	<b>Hazard ratios (95% CI)</b>  <u>1% HbA1c increments</u> = 1.09 (0.84,1.41)	Age, sex, duration of DM, systolic BP, non-HDL cholesterol, smoking status. eGFR (MDRD)
Kranenburg [27] Netherlands (2015)	SMART study  Total= 1687 Hx CVD= 1156 No Hx CVD= 531	18-80 yo	No vascular disease group = 59.0%	6.1 (3.1 - 9.5) yrs (median [IQR])	Patients referred to the medical centre Utrecht	T2DM	<b>Hazard ratios (95% CI)</b>  <u>1% HbA1c increments</u> = 1.40 (1.01,1.94)*	Age, sex, duration of DM, systolic BP, smoking status, non-HDL level, modification of diet in renal disease



Supplementary Table S6 (continued)...


Author (citation) Country of origin (Year published)	Study cohort  Sample size (n' participants)	Age (in years)	Sex (% male)	Follow-up (in years)	Ethnicity description	Diabetes status of participants assessed	Adjusted effect sizes (95% CI)	Covariates used in adjustment of adjusted effect sizes (95% CI) presented
<b>Camafort [32]</b> Spain (2011)	FRENA study  Total= 974	Adult mean +/- SD age = 69 +/- 9 yo	59% (in stroke patients)	1.17 yrs (mean)	Patients attending FRENA study hospitals	T2DM	<u>Relative risk (95% CI)</u> <u>Categorical HbA1c</u> ≥7.0%= reference <7.0%= 0.9 (0.4,1.9)	Age, gender, systolic BP, use of drugs, creatinine clearance levels, clinical presentation
<b>Lin [28]</b> Taiwan (2014)	National Diabetes Care Management Program  Total= 28354	≥30 yo	<u>Stratified by</u> <u>HbA1c:</u> <7.0%= 52.31% ≥7.0%= 45.22%	7.5 yrs (mean)	Ethnically Chinese participants	T2DM	<u>Hazard ratios (95% CI)</u> <u>Categorical HbA1c</u> <7.0%= reference 7.0 to 8.0%= 1.27 (1.13,1.43)* 8.0 to 9.0%= 1.55 (1.37,1.75)* ≥9.0%= 2.06 (1.85,2.31)*	Age and gender only
<b>Ashburner [39]</b> USA (2016)	ATRIA  Total= 2101 people with diabetes	≥18 yo	<u>Stratified by</u> <u>HbA1c:</u> <7%= 63.2% 7.0 to 8.9%= 60.4% ≥9.0%= 57.5%	2.48 +/- 2.23 yrs (mean +/- SD)	<u>&lt;7%:</u> White=86.5%, Black=3.5%, Other=0.7%, Asian/Pacific Islander=6.2%, Hispanic=3.1%  <u>7.0-8.9%:</u> White=85.7%, Black=5.1%, Other=0.6% Asian/Pacific Islander=6.4%, Hispanic=2.2%  <u>≥9.0%:</u> White=78.6%, Black=7.8%, Other=0.8% Asian/Pacific Islander=9.2%, Hispanic=3.9%	Mixed diabetes cohort	<u>Hazard ratios (95% CI)</u> <u>Categorical HbA1c</u> <7.0%= reference 7.0 to 8.9%= 1.09 (0.75,1.60) >9.0%= 1.10 (0.70,1.72)	<b>Unadjusted result</b> used as adjusted result includes adjustment for insulin use

Results presented represent the most adjusted hazard ratios (HR) or risk ratios (RR, relative risk) available in the source literature. Results presented only apply to participants with diabetes mellitus (T1DM, T2DM or unspecified type) in the source study. Mixed diabetes cohorts include T1DM, T2DM and/or unspecified diabetes type. Covariates listed are those used in adjustment of results quoted. Results adjusted for hypoglycaemic medication use were not selected. In these instances, the next most adjusted result(s) were selected. Where available, both continuous and categorical HR or RR data was included for each study. Statistically significant results are identified with \*. T1DM= type 1 diabetes mellitus, T2DM= type 2 diabetes mellitus, BP= blood pressure, TG= triglyceride, LDL= low density lipoprotein, HDL= high density lipoprotein, BMI= body mass index, WHR= waist-hip ratio, eGFR= estimated glomerular filtration rate, Hx= history, yo= years old, yrs= years, SD= standard deviation, IQR= interquartile range.

<input type="checkbox"/>	1	exp Hemoglobin A, Glycosylated/	28365	Advanced	<a href="#">Display Results</a>	<a href="#">More ▾</a>	
<input type="checkbox"/>	2	hba1c.tw.	23369	Advanced	<a href="#">Display Results</a>	<a href="#">More ▾</a>	
<input type="checkbox"/>	3	glycated hemoglobin.tw.	5354	Advanced	<a href="#">Display Results</a>	<a href="#">More ▾</a>	
<input type="checkbox"/>	4	glycated haemoglobin.tw.	2559	Advanced	<a href="#">Display Results</a>	<a href="#">More ▾</a>	
<input type="checkbox"/>	5	cerebral infarction.tw.	11375	Advanced	<a href="#">Display Results</a>	<a href="#">More ▾</a>	
<input type="checkbox"/>	6	cerebral hemorrhage.tw.	3617	Advanced	<a href="#">Display Results</a>	<a href="#">More ▾</a>	
<input type="checkbox"/>	7	cerebral haemorrhage.tw.	955	Advanced	<a href="#">Display Results</a>	<a href="#">More ▾</a>	
<input type="checkbox"/>	8	stroke.tw.	186643	Advanced	<a href="#">Display Results</a>	<a href="#">More ▾</a>	
<input type="checkbox"/>	9	transient ischemic attack.tw.	6472	Advanced	<a href="#">Display Results</a>	<a href="#">More ▾</a>	
<input type="checkbox"/>	10	transient ischaemic attack.tw.	1481	Advanced	<a href="#">Display Results</a>	<a href="#">More ▾</a>	
<input type="checkbox"/>	11	glycosylated hemoglobin.tw.	6312	Advanced	<a href="#">Display Results</a>	<a href="#">More ▾</a>	
<input type="checkbox"/>	12	glycosylated haemoglobin.tw.	2149	Advanced	<a href="#">Display Results</a>	<a href="#">More ▾</a>	
<input type="checkbox"/>	13	exp cerebrovascular disorders/ or exp basal ganglia cerebrovascular disease/ or exp brain ischemia/ or exp carotid artery diseases/ or exp cerebral small vessel diseases/ or exp cerebrovascular trauma/ or exp dementia, vascular/ or exp intracranial arterial diseases/ or exp "intracranial embolism and thrombosis"/ or exp intracranial hemorrhages/ or exp stroke/ or exp vasculitis, central nervous system/ or exp vasospasm, intracranial/	315666	Advanced	<a href="#">Display Results</a>	<a href="#">More ▾</a>	
<input type="checkbox"/>	14	5 or 6 or 7 or 8 or 9 or 10 or 13	407020	Advanced	<a href="#">Display Results</a>	<a href="#">More ▾</a>	
<input type="checkbox"/>	15	1 or 2 or 3 or 4 or 11 or 12	46824	Advanced	<a href="#">Display Results</a>	<a href="#">More ▾</a>	
<input type="checkbox"/>	16	14 and 15	1141	Advanced	<a href="#">Display Results</a>	<a href="#">More ▾</a>	
<input type="checkbox"/>	17	1 and 13	351	Advanced	<a href="#">Display Results</a>	<a href="#">More ▾</a>	
<input type="checkbox"/>	18	limit 16 to animals	18	Advanced	<a href="#">Display Results</a>	<a href="#">More ▾</a>	
<input type="checkbox"/>	19	16 not 18	1123	Advanced	<a href="#">Display Results</a>	<a href="#">More ▾</a>	


### **Supplementary Figure S1: Summary of search terms and Boolean operators used within the search strategy in MEDLINE**

Search terms including MeSH and text-word terms together with Boolean operators, ‘explosion’ functions and filters applied are described. After filtering for human only studies a total of 1,123 results were obtained from the MEDLINE search. Search results depicted reflect the most recent (repeat) search performed on 5<sup>th</sup> Mar 2017. Synonymous searches were performed in the remaining four databases. Two searches using the same search strategy (as depicted above) were performed across all five databases, on 7<sup>th</sup> Feb 2017 and 5<sup>th</sup> Mar 2017, for completeness.




**Supplementary Figure S2: Association between ADA-defined pre-diabetes range HbA1c (5.7%-6.5%) and first-ever stroke risk**

Studies which used a reference category of HbA1c within the non-diabetes range (<5.7%) and a comparator range of HbA1c within pre-diabetes range HbA1c (5.7%-6.5%) were included within random-effects model meta-analysis performed. Pooled meta-analytical effect sizes (ES) (95% CI) presented reflect meta-analytical generated hazard ratios (HR) (95% CI). Risk ratio (RR, relative risk) data were treated as equivalent to hazard ratios (HR). Weights (%) used in the meta-analysis were generated using an inverse-variance method. The reference category used (ES=1.0) reflects non-diabetes range HbA1c (<5.7%).



**Supplementary Figure S3: Association between ADA-defined diabetes range HbA1c (≥6.5%) and first-ever stroke risk**

Studies which used a reference category of HbA1c within the non-diabetes range (<5.7%) and a comparator range of HbA1c within diabetes range HbA1c (≥6.5%) were included within random-effects model meta-analysis performed. Pooled meta-analytical effect sizes (ES) (95% CI) presented reflect meta-analytical generated hazard ratios (HR) (95% CI). Risk ratio (RR, relative risk) data were treated as equivalent to hazard ratios (HR). Weights (%) used in the meta-analysis were generated using an inverse-variance method. The reference category used (ES=1.0) reflects non-diabetes range HbA1c (<5.7%).



```
. regress log_ES HbA1c
```

Source	SS	df	MS	Number of obs	=	23
Model	1.4259195	1	1.4259195	F(1, 21)	=	23.69
Residual	1.26411504	21	.060195954	Prob > F	=	0.0001
Total	2.69003454	22	.122274297	R-squared	=	0.5301
				Adj R-squared	=	0.5077
				Root MSE	=	.24535

log_ES	Coef.	Std. Err.	t	P> t	[95% Conf. Interval]
HbA1c	.225322	.0462956	4.87	0.000	.129045 .3215989
_cons	-1.150402	.2783665	-4.13	0.000	-1.729297 -.5715076

**Supplementary Figure S4: Linear regression analysis used to confirm linear hypothesis used in estimation of 1% HbA1c data**

Studies presenting data for the association between inter-categorical HbA1c(%) elevations and first-ever stroke risk, in non-diabetes cohorts, were used. Risk ratios (RR, relative risk) were treated as equivalent to hazard ratios (HR). A series of (x,y) co-ordinates (HbA1c point value, ln(HR)) were generated and used within linear regression analysis demonstrated. Significance for linear fit was set at  $p < 0.05$ . A two-way graph was constructed to visually assess the linear regression fit for the data set. log-transformed HR (95% CI) = natural logarithm (ln) transformed HR (95% CI).

-> Study = Selvin et al 2013 (ARIC)

Source	SS	df	MS	Number of obs	=	3
Model	.396617203	1	.396617203	F(1, 1)	=	41.37
Residual	.009586536	1	.009586536	Prob > F	=	0.0982
Total	.406203739	2	.20310187	R-squared	=	0.9764
				Adj R-squared	=	0.9528
				Root MSE	=	.09791


log_ES	Coef.	Std. Err.	t	P> t	[95% Conf. Interval]	
HbA1c	.4251409	.0660964	6.43	0.098	-.4146938	1.264975
_cons	-2.206962	.4153153	-5.31	0.118	-7.484043	3.070119

**Log-transformed effect size (95% CI)= 0.425 (-0.415,1.265)**

**Exponentiated effect size (95% CI)= 1.53 (0.66,3.54)**


**Supplementary Figure S5: 1% HbA1c increment effect size (95% CI) estimation method using the example of Selvin [11]**

Inter-categorical HR (95% CI) data presented in Selvin [11] were extrapolated and used to create a series of (x,y) co-ordinates corresponding to (HbA1c point value, ln(HR)). A linear regression model was used to calculate the natural logarithm values corresponding to estimated 1% HbA1c increment ln(HR) and ln(95% CI), as shown above. These values were then used in ensuing random-effects model meta-analyses and sensitivity analyses. log-transformed HR (95% CI)= natural logarithm (ln) transformed HR (95% CI).



### Supplementary Figure S6: Sensitivity analysis for inadequate covariate adjustment in study-quoted 1% HbA1c increment data


A moderate  $I^2$  statistic was calculated when all available diabetes cohort studies examining a first-ever stroke outcome were included within random-effects meta-analysis, as shown ( $I^2=59.0\%$ ,  $p=0.012$ ). Risk ratio (RR, relative risk) data was treated as equivalent to hazard ratio (HR) data. Weights (%) were calculated using the inverse-variance method. Exclusion of studies with very limited covariate adjustment use in covariate-adjusted effect size calculation (Zhao [29] and Giorda [30]) resulted in a reduction in  $I^2$  statistic magnitude (from moderate to low) without significantly altering the meta-analytical effect sizes (ES[95% CI]= 1.17 [1.09,1.25],  $I^2=41.9\%$  [ $p=0.111$ ]). Effect sizes (ES) represent hazard ratios (HR). T1DM= type 1 diabetes, T2DM= type 2 diabetes, mixed diabetes= type 1 or type 2 diabetes.



### Supplementary Figure S7: Sensitivity analysis for inadequate covariate adjustment in estimated 1% HbA1c increment data


A high  $I^2$  statistic value was present when all available diabetes cohort studies examining a first-ever stroke outcome were included within random-effects meta-analysis, as shown ( $I^2=89.9\%$ ,  $p<0.001$ ). Risk ratio (RR, relative risk) data was treated as equivalent to hazard ratio (HR) data. Weights (%) were calculated using the inverse-variance method. Exclusion of studies with very limited covariate adjustment use in covariate-adjusted effect size calculation (Kong [7], Zhao [29], Cederholm [8]) resulted in a reduction in the  $I^2$  statistic value (from high to moderate) without significantly altering the meta-analytical effect sizes (ES[95% CI]= 1.17 [1.01,1.36],  $I^2=57.7\%$  [ $p=0.051$ ]). Effect sizes (ES) represent hazard ratios (HR). T1DM= type 1 diabetes, T2DM= type 2 diabetes, mixed diabetes= type 1 or type 2 diabetes.






**Supplementary Figure S8: Comparison of study-quoted 1% HbA1c increment first-ever stroke and first-ever ischaemic stroke effects sizes, in non-diabetes cohorts**

Studies presenting 1% HbA1c increment data (or equivalent) for the association with first-ever stroke and first-ever ischaemic stroke outcomes, in non-diabetes cohorts, were used to assess the importance of ischaemic stroke subtype stratification on random-effects model meta-analytical outcomes derived. Risk ratio (RR, relative risk) data was treated as equivalent to hazard ratio (HR) data. 1 standard deviation data (1sd) was treated as equivalent to 1% HbA1c data. Effect sizes (ES) represent hazard ratios (HR).




**Supplementary Figure S9: Comparison of study-quoted 1% HbA1c increment first-ever stroke and first-ever ischaemic stroke effects sizes, in diabetes cohorts**

Studies presenting 1% HbA1c increment data (or equivalent) for the association with first-ever stroke and first-ever ischaemic stroke outcomes, in diabetes cohorts, were used to assess the importance of ischaemic stroke subtype stratification on random-effects model meta-analytical outcomes derived. Risk ratio (RR, relative risk) data was treated as equivalent to hazard ratio (HR) data. Effect sizes (ES) represent hazard ratios (HR). T1DM= type 1 diabetes, T2DM= type 2 diabetes and mixed diabetes = T1DM or T2DM cohorts.




**Supplementary Figure S10: Comparison of study-quoted and linear regression estimated 1% HbA1c effect size data**

Studies presenting continuous (1% increment or equivalent) and categorical HbA1c(%) effect size data were used to assess the accuracy of the linear regression estimation method used in estimated 1% HbA1c increment meta-analysis for the association with first-ever stroke. Estimated 1% HbA1c increment effect sizes were calculated and compared to reported 1% HbA1c increment effect sizes, through independent random-effects model meta-analyses. Risk ratio (RR, relative risk) data was treated as hazard ratio (HR) data. 1 standard deviation (1sd) HbA1c increment data was treated as equivalent to 1% HbA1c increment data. Effect sizes (ES) represent hazard ratios (HR). T1DM= type 1 diabetes and T2DM= type 2 diabetes.




**Supplementary Figure S11: Association between linear regression estimated rising 1% HbA1c increments and stratified first-ever stroke risk**

Studies presenting hazard ratio (HR) or risk ratio (RR, relative risk) data assessing the association between rising categorical range HbA1c(%) and first-ever stroke risk were used in the estimation of rising 1% HbA1c increment effect sizes. Effect sizes (ES) (95% CI) derived from random-effects model meta-analysis within each subgroup analysis represent hazard ratios (HR) (95% CI). Using a linearity assumption for the continuous relationship between HbA1c(%) and first-ever stroke risk, linear regression analyses were performed using log-transformed effect size (95% CI) data, in order to calculate estimated 1% HbA1c increment effect size (95% CI) equivalents from inter-categorical HbA1c data. Studies were stratified based on the diabetes status of their cohorts and their restriction of first-ever stroke to an ischaemic stroke subtype. The outcome ‘first-ever stroke’ only included studies which did not restrict their stroke outcome to first-ever ischaemic stroke. The outcome ‘first-ever ischaemic stroke’ only included studies which specifically restricted their stroke outcome to first-ever stroke of ischaemic subtype. Diabetes cohorts included studies which measured type 1 diabetes, type 2 diabetes or a combination of both. Non-diabetes cohorts represented studies which either used participants with no diabetes mellitus or whose effect size(s) were adjusted for diabetes. Pooled effect sizes (95% CI) are shown for each outcome subgroup. The  $I^2$  statistic values for each subgroup analysis assessing the percentage of variation across studies that is due to heterogeneity, rather than chance, are presented below each subgroup analysis. A random-effects model using the inverse-variance method for weighting was used to generate pooled-effect sizes (ES) (95% CI) for each subgroup presented. ES=1.0 indicates no statistically significant association between rising 1% HbA1c increment in the subgroup analysis performed. Studies, identified through sensitivity analyses, which resulted in higher magnitude  $I^2$  statistic values due to insufficient covariate adjustment [7,8,29] were excluded from the analyses presented. T1DM= type 1 diabetes mellitus, T2DM= type 2 diabetes mellitus, mixed diabetes cohort= cohort with type 1 and type 2 diabetes mellitus participants.



Egger's test

Std_Eff	Coef.	Std. Err.	t	P> t	[95% Conf. Interval]
slope	.4185779	.2779831	1.51	0.271	-.7774867 1.614642
bias	-1.285685	1.800184	-0.71	0.549	-9.03125 6.459881







Egger's test

Std_Eff	Coef.	Std. Err.	t	P> t	[95% Conf. Interval]
slope	.6778805	.3498638	1.94	0.192	-.8274619 2.183223
bias	.4538893	1.703781	0.27	0.815	-6.876889 7.784668


**Supplementary Figure S12: Publication bias assessment for inter-categorical meta-analyses within Supplementary Figures S2-S3**

Funnel plots with their corresponding Egger's results are presented for each of the inter-categorical ADA defined HbA1c meta-analyses within Supplementary Figures S2-S3. Funnel plot (A) and the corresponding Egger's test result corresponds to the inter-categorical analysis examining the risk of first-ever stroke when comparing pre-diabetes range HbA1c (5.7%-6.5%) to non-diabetes range HbA1c (<5.7%) (Supplementary Figure S2). Funnel plot (B) and the corresponding Egger's test result corresponds to the inter-categorical analysis examining the risk of first-ever stroke when comparing diabetes range HbA1c ( $\geq$ 6.5%) to non-diabetes range HbA1c (<5.7%) (Supplementary Figure S3). Significance for funnel plot asymmetry was set at  $p < 0.05$  for the Egger's bias result shown. Log Effect Size (ES)= natural logarithm of effect sizes.







### Supplementary Figure S13: Publication bias assessment for subgroup meta-analyses within Figure 2

Funnel plots with their corresponding Egger's results are presented for each of the subgroup meta-analyses presented within Figure 2. Funnel plot (A) and the corresponding Egger's test result corresponds to the subgroup analysis 'First-ever stroke (cohorts without diabetes)'. Funnel plot (B) and the corresponding Egger's test result corresponds to the subgroup analysis 'First-ever stroke (cohorts with diabetes)'. Funnel plot (C) and the corresponding Egger's test result corresponds to the subgroup analysis 'First-ever ischaemic stroke (cohorts without diabetes)'. Funnel plot (D) and the corresponding Egger's test result corresponds to the subgroup analysis 'First-ever ischaemic stroke (cohorts with diabetes)'. Significance for funnel plot asymmetry was set at  $p < 0.05$  for the Egger's bias results shown. Log Effect Size (ES) = natural logarithm of effect sizes.



**Supplementary Figure S14: Publication bias assessment for sensitivity analysis within Supplementary Figure S6**


The funnel plot and its corresponding Egger's results are shown for the sensitivity analysis presented within Supplementary Figure S6. Significance for funnel plot asymmetry was set at  $p < 0.05$  for the Egger's bias result shown. Log Effect Size (ES) = natural logarithm of effect sizes.



**Supplementary Figure S15: Publication bias assessment for subgroup meta-analyses within Supplementary Figure S11**


Funnel plots with their corresponding Egger's results are presented for each of the subgroup meta-analyses presented within Supplementary Figure S11. Funnel plot (A) and the corresponding Egger's test result corresponds to the subgroup analysis 'First-ever stroke (cohorts without diabetes)'. Funnel plot (B) and the corresponding Egger's test result corresponds to the subgroup analysis 'First-ever stroke (cohorts with diabetes)'. Funnel plot (C) and the corresponding Egger's test result corresponds to the subgroup analysis 'First-ever ischaemic stroke (cohorts without diabetes)'. Funnel plot (D) and the corresponding Egger's test result corresponds to the subgroup analysis 'First-ever ischaemic stroke (cohorts with diabetes)'. Significance for funnel plot asymmetry was set at  $p < 0.05$  for the Egger's bias results shown. Log Effect Size (ES) = natural logarithm of effect sizes.






**Supplementary Figure S16: Publication bias assessment for sensitivity analysis within Supplementary Figure S7**

The funnel plot and its corresponding Egger's results are shown for the sensitivity analysis presented within Supplementary Figure S7. Significance for funnel plot asymmetry was set at  $p < 0.05$  for the Egger's bias result shown. Log Effect Size (ES) = natural logarithm of effect sizes.




**Supplementary Figure S17: Additional subgroup analysis: Association between study-quoted rising 1% HbA1c increments and first-ever stroke in non-diabetes and diabetes cohorts (as described in Figure 2)**

Studies presenting hazard ratio (HR) or risk ratio (RR, relative risk) data assessing the association between rising 1% HbA1c increments and first-ever stroke risk were identified and used to calculate meta-analytical effect sizes (ES) (95% CI). RR data was treated as equivalent to HR data. Studies using 1 standard deviation (1sd) HbA1c increments for effect sizes quoted were treated as equivalent to 1% HbA1c increment data. The corresponding HbA1c increment for each standard deviation are as shown in brackets provided. Studies were stratified based on the diabetes status of their cohorts and their restriction of first-ever stroke to an ischaemic stroke subtype. The outcome ‘first-ever stroke’ reflects any stroke subtype. The outcome ‘first-ever ischaemic stroke’ only included studies which specifically restricted their stroke outcome to first-ever stroke of ischaemic subtype. Diabetes cohorts included studies which measured type 1 diabetes (T1DM), type 2 diabetes (T2DM) or a combination of both (mixed diabetes cohort). Non-diabetes cohorts represented studies which used participants with no diabetes mellitus or whose effect size(s) were adjusted for diabetes. The  $I^2$  statistic values for each subgroup analysis assessing the percentage of variation across studies that is due to heterogeneity, rather than chance, are presented below each subgroup analysis. A random-effects model using the inverse-variance method for weighting was used to generate pooled effect sizes for each subgroup. ES=1.0 indicates no statistically significant association.




**Supplementary Figure S18: Additional subgroup analysis: Association between study-quoted rising 1% HbA1c increments and first-ever ischaemic stroke in non-diabetes and diabetes cohorts (as described in Figure 2)**

Studies presenting hazard ratio (HR) or risk ratio (RR, relative risk) data assessing the association between rising 1% HbA1c increments and first-ever stroke risk were identified and used to calculate meta-analytical effect sizes (ES) (95% CI). RR data was treated as equivalent to HR data. Studies using 1 standard deviation (1sd) HbA1c increments for effect sizes quoted were treated as equivalent to 1% HbA1c increment data. The corresponding HbA1c increment for each standard deviation are as shown in brackets provided. Studies were stratified based on the diabetes status of their cohorts and their restriction of first-ever stroke to an ischaemic stroke subtype. The outcome ‘first-ever stroke’ reflects any stroke subtype. The outcome ‘first-ever ischaemic stroke’ only included studies which specifically restricted their stroke outcome to first-ever stroke of ischaemic subtype. Diabetes cohorts included studies which measured type 1 diabetes (T1DM), type 2 diabetes (T2DM) or a combination of both (mixed diabetes cohort). Non-diabetes cohorts represented studies which used participants with no diabetes mellitus or whose effect size(s) were adjusted for diabetes. The  $I^2$  statistic values for each subgroup analysis assessing the percentage of variation across studies that is due to heterogeneity, rather than chance, are presented below each subgroup analysis. A random-effects model using the inverse-variance method for weighting was used to generate pooled effect sizes for each subgroup. ES=1.0 indicates no statistically significant association.




**Supplementary Figure S19: Additional subgroup analysis: Association between study-quoted rising 1% HbA1c increments and the combined outcome of first-ever stroke and first-ever ischaemic stroke events, in non-diabetes cohorts**

Studies presenting hazard ratio (HR) or risk ratio (RR, relative risk) data assessing the association between rising 1% HbA1c increments and first-ever stroke risk were identified and used to calculate meta-analytical effect sizes (ES) (95% CI). RR data was treated as equivalent to HR data. Studies using 1 standard deviation (1sd) HbA1c increments for effect sizes quoted were treated as equivalent to 1% HbA1c increment data. The corresponding HbA1c increment for each standard deviation are as shown in brackets provided. The data presented depicts the association between rising 1% HbA1c increments and a combined outcome of first-ever stroke and first-ever ischaemic stroke strata (depicted in Figure 2), for studies using non-diabetes cohorts. The outcome ‘first-ever stroke’ reflects any stroke subtype and the outcome ‘first-ever ischaemic stroke’ only included studies which specifically restricted their stroke outcome to first-ever stroke of ischaemic subtype. Non-diabetes cohorts represented studies which used participants with no diabetes mellitus or whose effect size(s) were adjusted for diabetes. The I<sup>2</sup> statistic values for each subgroup analysis assessing the percentage of variation across studies that is due to heterogeneity, rather than chance, are presented below each subgroup analysis. A random-effects model using the inverse-variance method for weighting was used to generate pooled effect sizes for each subgroup. ES=1.0 indicates no statistically significant association. Chen [15] was excluded from this analysis to avoid bias attributable to duplicate study cohort




**Supplementary Figure S20: Additional subgroup analysis: Association between study-quoted rising 1% HbA1c increments and the combined outcome of first-ever stroke and first-ever ischaemic stroke events, in diabetes cohorts**

Studies presenting hazard ratio (HR) or risk ratio (RR, relative risk) data assessing the association between rising 1% HbA1c increments and first-ever stroke risk were identified and used to calculate meta-analytical effect sizes (ES) (95% CI). RR data was treated as equivalent to HR data. Studies using 1 standard deviation (1sd) HbA1c increments for effect sizes quoted were treated as equivalent to 1% HbA1c increment data. The data presented depicts the association between rising 1% HbA1c increments and a combined outcome of first-ever stroke and first-ever ischaemic stroke strata (depicted in Figure 2), for studies using diabetes cohorts. The outcome ‘first-ever stroke’ reflects any stroke subtype and the outcome ‘first-ever ischaemic stroke’ only included studies which specifically restricted their stroke outcome to first-ever stroke of ischaemic subtype. Diabetes cohorts included studies which measured type 1 diabetes (T1DM), type 2 diabetes (T2DM) or a combination of both (mixed diabetes cohort). The I<sup>2</sup> statistic values for each subgroup analysis assessing the percentage of variation across studies that is due to heterogeneity, rather than chance, are presented below each subgroup analysis. A random-effects model using the inverse-variance method for weighting was used to generate pooled effect sizes for each subgroup. ES=1.0 indicates no statistically significant association. Hagg [23] and Chen [15] have been excluded from this analysis to avoid bias attributable to duplicate study cohort inclusion.




**Supplementary Figure S21: Additional subgroup analysis: Association between study-quoted rising 1% HbA1c increments and the combined outcome of first-ever stroke and first-ever ischaemic stroke events, regardless of cohort diabetes status (combination of Supplementary Figures S19 and S20)**

Studies presenting hazard ratio (HR) or risk ratio (RR, relative risk) data assessing the association between rising 1% HbA1c increments and first-ever stroke risk were identified and used to calculate meta-analytical effect sizes (ES) (95% CI). RR data was treated as equivalent to HR data. Studies using 1 standard deviation (1sd) HbA1c increments for effect sizes quoted were treated as equivalent to 1% HbA1c increment data. The corresponding HbA1c increment for each standard deviation are as shown in brackets provided. The data presented depicts the association between rising 1% HbA1c increments and a combined outcome of first-ever stroke and first-ever ischaemic stroke strata (depicted in Figure 2), for studies using non-diabetes or diabetes cohorts. The outcome ‘first-ever stroke’ reflects any stroke subtype and the outcome ‘first-ever ischaemic stroke’ only included studies which specifically restricted their stroke outcome to first-ever stroke of ischaemic subtype. Diabetes cohorts included studies which measured type 1 diabetes (T1DM), type 2 diabetes (T2DM) or a combination of both (mixed diabetes cohort). Non-diabetes cohorts represented studies which used participants with no diabetes mellitus or whose effect size(s) were adjusted for diabetes. The  $I^2$  statistic values for each subgroup analysis assessing the percentage of variation across studies that is due to heterogeneity, rather than chance, are presented below each subgroup analysis. A random-effects model using the inverse-variance method for weighting was used to generate pooled effect sizes for each subgroup. ES=1.0 indicates no statistically significant association. Hagg [23] and Chen [15] have been excluded from this analysis to avoid bias attributable to duplicate study cohort inclusion.



**Supplementary Figure S22: Additional subgroup analysis: Association between first-ever stroke risk and combined ADA-defined pre-diabetes and diabetes range HbA1c ( $\geq 5.7\%$ ), compared to non-diabetes range HbA1c ( $< 5.7\%$ )**

Studies which used a reference category of HbA1c within the non-diabetes range ( $< 5.7\%$ ) and a comparator range of HbA1c within pre-diabetes range HbA1c ( $5.7\% - 6.5\%$ ) or diabetes range HbA1c ( $\geq 6.5\%$ ) were included within random-effects model meta-analysis performed. Pooled meta-analytical effect sizes (ES) (95% CI) presented reflect meta-analytical generated hazard ratios (HR) (95% CI). Risk ratio (RR, relative risk) data were treated as equivalent to hazard ratios (HR). Weights (%) used in the meta-analysis were generated using an inverse-variance method. The reference category used (ES=1.0) reflects non-diabetes range HbA1c ( $< 5.7\%$ ).



**Supplementary Figure S23: Additional subgroup analysis: Comparison of study-quoted 1% HbA1c increment first-ever stroke and first-ever ischaemic stroke effect sizes regardless of cohort diabetes status (combination of Supplementary Figures S8 and S9)**

Studies presenting 1% HbA1c increment data (or equivalent) for the association with first-ever stroke and first-ever ischaemic stroke outcomes, in non-diabetes and diabetes cohorts, were used to assess the importance of ischaemic stroke subtype stratification on random-effects model meta-analytical outcomes derived in Supplementary Figures S8, S9, S19 and S20. Risk ratio (RR, relative risk) data was treated as equivalent to hazard ratio (HR) data. 1 standard deviation data (1sd) was treated as equivalent to 1% HbA1c data. Effect sizes (ES) represent hazard ratios (HR). The analysis presented within this Supplementary Figure (S23) presents the pooled effect size when the studies presented within Supplementary Figures S8 and S9 are pooled within the same meta-analysis.



## Data supplement references:

---

1. SIGN Methodology Checklist 3: Cohort studies. Scotland: Scottish Intercollegiate Guideline Network; 2012. Available from: [http://www.sign.ac.uk/assets/checklist\\_for\\_cohort\\_studies.rtf](http://www.sign.ac.uk/assets/checklist_for_cohort_studies.rtf). Accessed 21 March, 2017.
2. Greenland S. Quantitative methods in the review of epidemiologic literature. *Epidemiologic Reviews*. 1987;9:1-30.
3. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH. Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus. *Ann Intern Med*. 2004;141:421-431.
4. Zhang Y, Hu G, Yuan Z, Chen L. Glycosylated Hemoglobin in Relationship to Cardiovascular Outcomes and Death in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. *PLoS One*. 2012;7:e42551.
5. Karas MG, Devereux RB, Wiebers DO, Whisnant JP, Best LG, Lee ET, Howard BV, Roman MJ, Umans JG, Kizer JR. Incremental Value of Biochemical and Echocardiographic Measures in Prediction of Ischemic Stroke: The Strong Heart Study. *Stroke*. 2012;43:720-726.
6. Skriver MV, Stovring H, Kristensen JK, Charles M, Sandbaek A. Short-term impact of HbA1c on morbidity and all-cause mortality in people with type 2 diabetes: a Danish population-based observational study. *Diabetologia*. 2012;55:2361-2370.
7. Kong APS, Yang X, Ko GTC, So WY, Chan WB, Ma RCW, Ng VWS, Chow CC, Cockram CS, Tong PCY, Wong V, Chan JCN. Effects of Treatment Targets on Subsequent Cardiovascular Events in Chinese Patients With Type 2 Diabetes. *Diabetes Care*. 2007;30:953-959.
8. Cederholm J, Zethelius B, Nilsson PM, Eeg-Olofsson K, Eliasson B, Gudbjornsdottir S, on behalf of the Swedish National Diabetes Register. Effect of tight control of HbA1c and blood pressure on cardiovascular diseases in type 2 diabetes: An observational study from the Swedish National Diabetes Register (NDR). *Diabetes Research and Clinical Practice*. 2009;86:74-81.
9. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, Coresh J, Brancati FL. Glycated Hemoglobin, Diabetes, and Cardiovascular Risk in Nondiabetic Adults. *NEJM*. 2010;362:800-811.

10. Selvin E, Rawlings AM, Lutsey PL, Maruthur N, Pankow JS, Steffes M, Coresh J. Fructosamine and Glycated Albumin and the Risk of Cardiovascular Outcomes and Death. *Circulation*. 2015;132:269-277.
11. Selvin E, Rawlings AM, Bergenstal RM, Coresh J, Brancati FL. No Racial Differences in the Association of Glycated Hemoglobin With Kidney Disease and Cardiovascular Outcomes. *Diabetes Care*. 2013;36:2995-3001.
12. Wang H, Shara NM, Lee ET, Devereux R, Calhoun D, de Simone G, Umans JG, Howard BV. Hemoglobin A1c, Fasting Glucose, and Cardiovascular Risk in a Population With High Prevalence of Diabetes: The Strong Heart Study. *Diabetes Care*. 2011;34:1952-1958.
13. Birkenhager-Gillesse EG, den Elzen WPJ, Achterberg WP, Mooijaart SP, Gussekloo J, de Craen AJM. Association Between Glycosylated Hemoglobin and Cardiovascular Events and Mortality in Older Adults without Diabetes Mellitus in the General Population: The Leiden 85-Plus Study. *Journal of the American Geriatrics Society*. 2015;63:1059-1066.
14. Lawlor DA, Fraser A, Ebrahim S, Smith GD. Independent Associations of Fasting Insulin, Glucose and Glycated Haemoglobin with Stroke and Coronary Heart Disease in Older Women. *PLoS Medicine*. 2007;4:e263 .
15. Chen YY, Lin YJ, Chong E, Chen PC, Chao TF, Chen SA, Chien KL. The Impact of Diabetes Mellitus and Corresponding HbA1c Levels on the Future Risks of Cardiovascular Disease and Mortality: A Representative Cohort Study in Taiwan. *PLoS One*. 2015;10:e0123116.
16. Goto A, Noda M, Matsushita Y, Goto M, Kato M, Isogawa A, Takahashi Y, Kurotani K, Oba S, Nanri A, Mizoue T, Yamagishi K, Yatsuya H, Saito I, Kokubo Y, Sawada N, Inoue M, Iso H, Kadowaki T, Tsugane S, JPHC Study Group. Hemoglobin A1c Levels and the Risk of Cardiovascular Disease in People Without Known Diabetes: A Population-Based Cohort Study in Japan. *Medicine*. 2015;94:e785.
17. Chonchol M, Katz R, Fried LF, Sarnak MJ, Siscovick DS, Newman AB, Strotmeyer ES, Bertoni A, Shlipak MG. Glycosylated hemoglobin and the risk of death and cardiovascular mortality in the elderly. *Nutrition, Metabolism and Cardiovascular Diseases*. 2010;20:15-21.
18. Ikeda F, Doi Y, Ninomiya T, Hirakawa Y, Mukai N, Hata J, Shikata K, Yoshida D, Matsumoto T, Kitazono T, Kiyohara Y. Haemoglobin A1c even within non-diabetic level is a predictor of

- cardiovascular disease in a general Japanese population: the Hisayama Study. *Cardiovascular Diabetology*. 2013;12:164.
19. Myint PK, Sinha S, Wareham NJ, Bingham SA, Luben RN, Welch AA, Khaw KT. Glycated Hemoglobin and Risk of Stroke in People Without Known Diabetes in the European Prospective Investigation Into Cancer (EPIC)-Norfolk Propsective Populaton Study: A Theshold Relationship?. *Stroke*. 2007;38:271-275.
  20. Wu S, Shi Y, Wang C, Jia Q, Zhang N, Zhao X, Liu G, Wang Y, Liu L, Wang Y, On Behalf of the Investigators for the Survey on Abnormal Glucose Regulation in Patients With Acute Stroke Across China (ACROSS-China). Glycated Hemoglobin Independently Predicts Stroke Recurrence within One Year after Acute First-Ever Non-Cardioembolic Strokes Onset in A Chinese Cohort Study. *PLoS One*. 2013;8:e80690.
  21. Stahl CH, Lind M, Svensson AM, Gudbjornsdottir S, Martensson A, Rosengren A. Glycaemic control and excess risk of ischaemic and haemorrhagic stroke in patients with type 1 diabetes: a cohort study of 33 453 patients. *Journal of Internal Medicine*. 2017;281:261-272.
  22. Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Svensson AM, Gudbjornsdottir S, Eliasson B. Glycemic Control and Cardiovascular Disease in 7,454 Patients With Type 1 Diabetes: An observational study from the Swedish National Diabetes Register (NDR). *Diabetes Care*. 2010;33:1640-1646.
  23. Hagg S, Thorn LM, Forsblom CM, Gordin D, Saraheimo M, Tolonen N, Waden J, Liebkind R, Putaala J, Tatlisumak T, Groop PH on behalf of the FinnDiane Study Group. Different Risk Factor Profiles for Ischemic and Hemorrhagic Stroke in Type 1 Diabetes Mellitus. *Stroke*. 2014;45:2558-2562.
  24. Adler AI, Neil HAW, Manley SE, Holman RR, Turner RC for the UKPDS Study Group. Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom Prospective Diabetes Study (UKPDS 47). *American Heart Journal*. 1999;138:S353-S359.
  25. Kontopantelis E, Springate DA, Reeves D, Ashcroft DM, Rutter M, Buchan I, Doran T. Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study. *Diabetologia*. 2015;58:505-518.

26. Freemantle N, Danchin N, Calvi-Gries F, Vincent M, Home PD. Relationship of glycaemic control and hypoglycaemic episodes to 4-year cardiovascular outcomes in people with type 2 diabetes starting insulin. *Diabetes, Obesity and Metabolism*. 2016;18:152-158.
27. Kranenburg G, van der Graaf Y, van der Leeuw J, Nathoe HMW, de Borst GJ, Kappelle LJ, Visseren FLJ, Westerink J on behalf of the SMART Study Group. The Relation Between HbA1c and Cardiovascular Events in Patients With Type 2 Diabetes With and Without Vascular Disease. *Diabetes Care*. 2015;38:1930-1936.
28. Lin CC, Yang CP, Li CI, Liu CS, Chen CC, Lin WY, Hwang KL, Yang SY, Li TC. Visit-to-visit variability of fasting plasma glucose as predictor of ischemic stroke: competing risk analysis in a national cohort of Taiwan Diabetes Study. *BMC Medicine*. 2014;12:165.
29. Zhao W, Katzmarzyk PT, Horswell R, Wang Y, Johnson J, Hu G. Sex Differences in the Risk of Stroke and HbA1c among Diabetic Patients. *Diabetologia*. 2014;57:918-926.
30. Giorda CB, Avogaro A, Maggini M, Lombardo F, Mannucci E, Turco S, Alegiani SS, Raschetti R, Velussi M, Ferrannini E, The DAI Study Group. Incidence and Risk Factors for Stroke in Type 2 Diabetic Patients: The DAI Study. *Stroke*. 2007;38:1154-1160.
31. Elley CR, Kenealy T, Robinson E, Drury PL. Glycated haemoglobin and cardiovascular outcomes in people with Type 2 diabetes: a large prospective cohort study. *Diabetic Medicine*. 2008;25:1295-1301.
32. Camafort M, Alvarez-Rodriguez LR, Munoz-Torrero JFS, Sahuquillo JC, Lopez-Jimenez L, Coll R, Monreal M, the FRENA Investigators. Glucose control and outcome in patients with stable diabetes and previous coronary, cerebrovascular or peripheral artery disease. Findings from the FRENA Registry. *Diabetic Medicine*. 2011;28:73-80.
33. Bots SH, van der Graaf Y, Nathoe HMW, de Borst GJ, Kappelle JL, Visseren FLJ, Westerink J, on behalf of the SMART Study Group. The influence of baseline risk on the relation between HbA1c and risk for new cardiovascular events and mortality in patients with type 2 diabetes and symptomatic cardiovascular disease. *Cardiovascular Diabetology*. 2016;15:101.
34. Hayashi T, Araki A, Kawashima S, Sone H, Watanabe H, Ohru T, Yokote K, Takemoto M, Kubota K, Noda M, Noto H, Ina K, Nomura H, Japan CDM group. Metabolic predictors of ischemic heart disease

and cerebrovascular attack in elderly diabetic individuals: difference in risk by age. *Cardiovascular Diabetology*. 2013;12:10.

35. Xu L, Chan WM, Hui YF, Lam TH. Association between HbA1c and cardiovascular disease mortality in older Hong Kong Chinese with diabetes. *Diabetic Medicine*. 2012;29:393-398.
36. Moss SE, Klein R, Klein BEK, Meuer SM. The Association of Glycemia and Cause-Specific Mortality in a Diabetic Population. *Arch Intern Med*. 1994;154:2473-2479.
37. Selvin E, Coresh J, Shahar E, Zhang L, Steffes M, Sharrett AR. Glycaemia (haemoglobin A1c) and incident ischaemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. *Lancet Neurology*. 2005;4:821-826.
38. Alter M, Lai SM, Friday G, Singh V, Kumar VM, Sobel E. Stroke Recurrence in Diabetics: Does Control of Blood Glucose Reduce Risk?. *Stroke*. 1997;28:1153-1157.
39. Ashburner JM, Go AS, Chang Y, Fang MC, Fredman L, Applebaum KM, Singer DE. Effect of Diabetes and Glycemic Control on Ischemic Stroke Risk in AF Patients: ATRIA Study. *Journal of the American College of Cardiology*. 2016;67:239-247.
40. Hirai FE, Moss SE, Klein BEK, Klein R. Relationship of Glycemic Control, Exogenous Insulin, and C-Peptide Levels to Ischemic Heart Disease Mortality Over a 16-Year Period in People With Older-Onset Diabetes: The Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR). *Diabetes Care*. 2008;31:493-497.